US20040191922A1 - Method and apparatus for desorption and ionization of analytes - Google Patents
Method and apparatus for desorption and ionization of analytes Download PDFInfo
- Publication number
- US20040191922A1 US20040191922A1 US10/728,442 US72844203A US2004191922A1 US 20040191922 A1 US20040191922 A1 US 20040191922A1 US 72844203 A US72844203 A US 72844203A US 2004191922 A1 US2004191922 A1 US 2004191922A1
- Authority
- US
- United States
- Prior art keywords
- analyte molecules
- analyte
- affinity reagent
- probe tip
- molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/02—Details
- H01J49/04—Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
- H01J49/0409—Sample holders or containers
- H01J49/0418—Sample holders or containers for laser desorption, e.g. matrix-assisted laser desorption/ionisation [MALDI] plates or surface enhanced laser desorption/ionisation [SELDI] plates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/405—Concentrating samples by adsorption or absorption
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
- G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction
Definitions
- This invention relates generally to methods and apparatus for desorption and ionization of analytes for the purpose of subsequent scientific analysis by such methods, for example, as mass spectrometry or biosensors. More specifically, this invention relates to the field of mass spectrometry, especially to the type of matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry used to analyze macromolecules, such as proteins or biomolecules.
- analysis by mass spectrometry involves the vaporization and ionization of a small sample of material, using a high energy source, such as a laser, including a laser beam.
- a high energy source such as a laser
- the material is vaporized from the surface of a probe tip by the laser beam, and in the process, some of the individual molecules are ionized by the gain of a proton.
- the positively charged ionized molecules are then accelerated through a short high voltage field and let fly into a high vacuum chamber, at the far end of which they strike a sensitive detector surface.
- the time of flight is a function of the mass of the ionized molecule
- the elapsed time between ionization and impact can be used to determine the molecule's mass which, in turn, can be used to identify the presence or absence of known molecules of specific mass.
- analyte fluids are available only in extremely small volumes (microliters) and may be needed for performing several different analyses. Therefore, even the small amount needed for preparation of the analyte/matrix crystalline mixture for a single analysis may be significant. Also, only a tiny fraction (a few thousandths or less) of analyte used in preparing the analyte/matrix mixture for use on the probe tip is actually consumed in the mass spectrometry analysis. Any improvement in the prior art procedure which made it possible to use much less analyte to conduct the test would be highly advantageous in many clinical areas.
- the analyte protein, or other macromolecule, used in preparing the analyte matrix for use on the probe tip is not suitable for any subsequent chemical tests or procedures because it is bound up in the matrix material.
- all of the matrix material used to date is strongly acidic, so that it would affect many chemical reactions which might be attempted on the mixture in order to modify the analyte molecules for subsequent examination. Any improvement in the procedure which made it possible to conduct subsequent chemical modifications or reactions on the analyte molecules, without removing them from the matrix or the probe tip, would be of enormous benefit to researchers and clinicians.
- matrix adduct formation of analyte-matrix complex which interferes with the accuracy of analyte measurement
- the primary object of the invention is to provide improved methods, materials composition and apparatus for coupled adsorption, desorption and ionization of multiple or selected analytes into the gas (vapor) phase, preferably for use in conjunction with mass spectrometry of biomolecules and other macromolecules, as well as by means of analytic detection other than mass spectrometry.
- the invention incudes a flexible variety of options for presenting surfaces with attached energy absorbing molecules, defined reaction sites, and affinity reagents for the capture,e transfer, and/or the desorption of analytes before and after a sseries of chemical, physical, and/or enzymatic modifications performed in situ.
- Another object is to provide such a method and apparatus for affinity-directed detection of analytes, including desorption and ionization of analytes in which the analyte is not dispersed in a matrix solution or crystalline structure but is presented within, on or above an attached surface of energy absorbing “matrix” material through molecular recognition events, in a position where it is accessible and amenable to a wide variety of chemical, physical and biological modification or recognition reactions.
- the probe surface with and without bonded energy absorbing molecules referred to as the sample presenting surface can be composed of a variety of materials, including porous or nonporous materials, with the porous materials providing sponge-like, polymeric, high surface areas for optimized adsorption and presentation of analyte.
- These surface materials can be substituted (at varying densities) with chemically bonded (covalent or noncovalent) affinity adsorption reagents and/or chemically bonded (i.e., immobilized) energy absorbing molecules (bound “matrix” molecules).
- the geometry of the sample presenting surface can be varied (i.e., size, texture, flexibility, thickness, etc.) to suit the need (e.g., insertion into a living organism through spaces of predetermined sizes) of the experiment (assay).
- Another object is to provide such a method and apparatus in which the analyte material is chemically bound or physically adhered to a substrate forming a probe tip or other sample presenting surface.
- a further object is to provide means for the modification of probe or sample presenting surfaces with energy-absorbing molecules to enable the successful desorption of analyte molecules without the addition of exogenous matrix molecules as in prior art.
- a further object is to provide the appropriate density of energy-absorbing molecules bonded (covalently or noncovalently) in a variety of geometries such that mono layers and multiple layers of attached energy-absorbing molecules can be used to facilitate the desorption of analyte molecules of varying masses.
- the optimum ratio of adsorbed or bonded energy-absorbing molecules to analyte varies with the mass of the analyte to be detected.
- a further object is to modify the sample presenting surface with such energy-absorbing molecules where the composition of the probe or sample presenting surface is other than the metal or metallic surfaces as described in prior art.
- a further object is to provide all combinations of surfaces modified with energy-absorbing molecules and/or affinity-directed analyte capture devices to enable the selective and/or nonselective adsorption of analytes and the subsequent desorption either with or without requiring the subsequent addition of additional matrix molecules. It is important to note that the surfaces modified with affinity reagents for the capture of analytes are-more useful than the underivitized sample surfaces described in prior art even when the deposition of energy-absorbing molecules (that is matrix) is as described in prior art. Because of the advantages in the ability to remove contaminating substances from the adsorbed analyte molecules and because of the ability to modify adsorbed analyte molecules without (or before) added matrix.
- a further object is to provide such a method and apparatus in which the substrate forming the probe tip or other sample presenting surface is derivatized with one or more affinity reagents (a variety of densities and degrees of amplification) for selective bonding with predetermined analytes or classes of analytes.
- affinity reagents a variety of densities and degrees of amplification
- a further object is to provide methods and apparatus for using probe tips having surfaces derivatized with affinity reagents and containing laser desorption matrix material (chemically bonded to surface or not) which may be used to isolate target analyte materials from undifferentiated biological samples such as blood, tears, urine, saliva, gastrointestinal fluids, spinal fluid, amniotic fluid, bone marrow, bacteria, viruses, cells in culture, biopsy tissue, plant tissue or fluids, insect tissue or fluids, etc.
- undifferentiated biological samples such as blood, tears, urine, saliva, gastrointestinal fluids, spinal fluid, amniotic fluid, bone marrow, bacteria, viruses, cells in culture, biopsy tissue, plant tissue or fluids, insect tissue or fluids, etc.
- a further object is to use analyte detection methods other than the generic electron multipliers typically used in mass spectrometric devices. This would include but would not be limited to detection films/plates for the qualitative or quantitative evaluation of fluorescent or radio-labeled anialytes or analyte molecule complexes.
- a further object is to provide such a system in which the affinity reagent chemically bonds or biologically adheres to the target analyte or class of analytes.
- a further object is to use existing and new solid phase affinity reagents (e.g., small diameter porous or nonporous beads of crosslineated polymer with attached molecular capture devices) designed for the (1) capture (adsorption of one or more analytes, (2) the preparation of these captured analytes (e.g., washing with H 2 O or other buffered or nonbuffered solutions to remove contaminants such as salts, multiple cycles of washing, such as with polar organic solvent, detergent-dissolving solvent, dilute acid, dilute base or urea), and (3) most importantly, the direct transfer of these captured and prepared analytes to the probe surface for subsequent analyte desorption (for detection, quantification and/or mass analysis).
- solid phase affinity reagents e.g., small diameter porous or nonporous beads of crosslineated polymer with attached molecular capture devices designed for the (1) capture (adsorption of one or more analytes, (2) the preparation of these captured analytes (e.g., washing with H
- a further object is to provide such a system in which the predetermined analytes are individual biomolecules or other macromolecules or combinations of adjoined molecules (i.e., complexes).
- a still further object is to provide such a method and apparatus in which the matrix materials used are not strongly acidic, as in prior art matrices, but are chemically modified into the slightly acidic, neutral pH or strongly basic range of pH.
- a further object is to provide such a system in which the matrix material has a pH above 6.0.
- a still further object is to provide a method and apparatus for desorption and ionization of analytes in which unused portion of the analytes contained on the presenting surface remain chemically accessible, so that a series of chemical and/or enzymatic or other treatments (e.g., discovery of analyte-associated molecules by molecular recognition) of the analyte may be conducted on the probe tip or other presenting surface, in situ, followed by sequential analyses of the modified analyte by mass spectrometry.
- the analyte is adsorbed to the sample presenting surface and can be treated (modified in situ after the excess free matrix is removed (i.e., washed away).
- Matrix can be added back before analysis by mass spectrometry. Using this procedure, an analyte can be repeatedly tested for a variety of components by removing one matrix, modifying the analyte sample, re-applying the same or different matrix, analyzing the sample, etc.
- a further object is to provide a method and apparatus for the combined chemical and/or enzymatic modifications of target analytes for the purpose of elucidating primary, secondary, tertiary, or quaternary structure of the analyte and its components.
- a still further object is to provide such a method and apparatus in which the probe tips or other sample presenting surfaces are formed of a variety of materials, including electrically insulating materials (porous and nonporous), flexible or nonrigid materials, optically transparent materials (e.g., glass, including glass of varying densities, thicknesses, colors and with varying refractive indices), as well as less reactive, more biocompatible materials (e.g., biopolymers such as agarose, dextran, cellulose, starches, peptides, and fragments of proteins and of nucleic acids such as DNA (deoxyribonucleic acid) and RNA (ribonucleic acid). These surfaces can be chemically modified by the attachment of energy-absorbing molecules and/or affinity directed analyte capture molecules.
- Another object is to provide a method and apparatus for desorption and ionization of analyte materials in which cations other than protons (H + ) are utilized for ionization of analyte macromolecules.
- the laser or light source used to convey energy to the probe surface can employ a wavelength(s) that is(are) not fixed but can be varied according to the wavelength absorbed by the matrix (whether the matrix is added in the free form or is chemically bonded to the probe (sample presenting) surface).
- a variety of wavelengths (10 or more) defined by absorbance of matrix or energy absorbing surface can be utilized.
- Another object is to provide such a method and apparatus in which the probe tips or other sample presenting surfaces used for laser desorption/ionization time-of-flight mass spectrometry are magnetized and in which the matrix, affinity directed absorption molecules and/or analyte materials are magnetically adhered to such magnetized surface.
- a further object is a method and apparatus in which the matrix and/or analyte materials are adhered by any variety of chemical mechanisms to the sample presenting surface.
- a further objective is to provide energy-absorbing molecules which have been incorporated into other chemical structures (e.g., chemical or biological polymers) for the deposition (covalent or noncovalent) onto the sample presenting surface in a way that enables repetitious analyte desorption events without interference with chemical and/or enzymatic modifications of the analyte molecule(s) performed in situ.
- chemical structures e.g., chemical or biological polymers
- Another object is to provide sample presenting surfaces in a variety of sizes and configurations (up to 4“ ⁇ 4”) with multiple (up to 10,000 or more) spots (including spots down to ⁇ 0.001 inch diameter) of affinity reagents arranged in predetermined arrays for the selective adsorption of numerous different analytes (e.g., clinical chemical marker proteins) to enable a wide spectrum sampling of the macromolecular composition of biological samples/fluids.
- numerous different analytes e.g., clinical chemical marker proteins
- the present invention overcomes limitations and disabilities of the prior art by providing probe tips or sample plates whose surfaces have been derivatized with biospecific affinity reagents which will selectively bind specific groups or types of biomolecules or other analytes out of an undifferentiated sample (such as blood or urine).
- an undifferentiated sample such as blood or urine.
- Appropriate selection of the affinity reagents used to derivatize the probe tip surface therefore makes possible the selection from the undifferentiated sample and binding to the probe tip of the specific types or groups of biological or other macromolecules under investigation, or subsequent examination (e.g., quantification and/or structure elucidation) by mass spectrometry.
- probe tips used in the process of the invention need not be metal or metal-coated, as with prior art procedures.
- Research involved in the invention has involved glass and synthetic polymer surfaces such as polystyrene, polypropylene, polyethylene, polycarbonate and other polymers including biopolymers, for the probe tips which have been covalently or noncovalently derivatized for immobilization of specific reagents that will direct the selective adsorption of specific analytes.
- These surfaces will include immobilized metal ions, immobilized proteins, peptides, enzymes, and inhibitor molecules, immobilized DNA and RNA, immobilized antibodies, immobilized reducing agents, immobilized carbohydrates and lectins, immobilized dyes and immobilized protein surface domains involved in molecular recognition (e.g., dimerization domains and subunits).
- the preferred probe tip, or sample plate, for selective adsorption/presentation of sample for mass analysis are (1) stainless steel (or other metal) with a synthetic polymer coating (e.g., cross-linked dextran or agarose, nylon, polyethylene, polystyrene) suitable for covalent attachment of specific biomolecules or other nonbiological affinity reagents, (2) glass or ceramic, and/or (3) plastic (synthetic polymer).
- a synthetic polymer coating e.g., cross-linked dextran or agarose, nylon, polyethylene, polystyrene
- plastic synthetic polymer
- Two features of the invention are (1) the specific size and localization of the derivatized surface with respect to the laser beam and (2) the affinity directed presentation of specific analyte molecules (e.g., macromolecule or biopolymer) at a defined surface density or local concentration required for the efficient detection by laser desorption/ionization time-of-flight mass spectrometry.
- This can be accomplished by arranging the affinity adsorption “spots” (0.005 to 0.080 inch diameter) on the probe surface in a defined manner (400 to 1,000 spots could be placed on a surface about the size of a glass slide).
- pH modified chemical matrices can be used on these surfaces to facilitate desorption/ionization without disruption of conditions necessary for subsequent sample modification.
- prior art matrix materials used for biomolecular mass spectrometry are acidic.
- the exact chemical structure of the pH-modified matrices still are unknown.
- suitable neutralization of the matrix material it can be made largely passive to subsequent chemical or enzymatic reactions carried out on the analyte molecules presented on the derivatized probe tip surface by the biospecific affinity reagents. This makes possible the carrying out of chemical reactions on the analyte molecules presented on the probe tips.
- FIG. 1A is a mass spectrum of peptide mixtures using sinapinic acid pH 6.5 as the matrix.
- FIG. 1B is a mass spectrum of the same peptide mixtures after in situ addition of CuSO 4 .
- FIG. 2A is a mass spectrum of human casein phosphopeptide (R1-K18+5P) using sinapinic acid pH 6.5 as the matrix.
- FIG. 2B shows the mass spectrum of the same peptide after in situ alkaline phosphatase digestion for 5 and 10 min respectively.
- FIG. 2D shows the mass spectrum of the same peptide using dihydroxybenzoic acid pH 2 as the matrix, after in situ alkaline phosphatase digestion for 10 min.
- FIG. 3 is a mass spectrum histidine-rich glycoprotein (GHHPH) 5 G peptide using sinapinic acid pH 6.2 as the matrix before and after in situ digestion with carboxypeptidase P.
- FIG. 4 is a composite mass spectra of peptide mixtures using sinapinic acid as the matrix on glass, polypropylene-coated steel, polystyrene-coated steel and nylon probe tips.
- FIG. 5A is a mass spectrum of peptides unadsorbed by TSK SW-IDA-Cu(II).
- FIG. 5B is a mass spectrum of peptide adsorbed by TSK SW-IDA-Cu(II).
- FIG. 5C is a mass spectrum of the same peptide adsorbed on TSK SW-IDA-Cu(II) after water wash.
- FIG. 6 is a mass spectrum of myoglobin ( ⁇ 8 fmole) affinity-adsorbed on TSK SW-IDA-Cu(II).
- FIG. 7A is a mass spectrum of proteins/peptides in infant formula.
- FIG. 7B is a mass spectrum of phosphopeptides in the same sample affinity-adsorbed on Sepharose-TED-Fe(III).
- FIG. 7C is a mass spectrum of proteins/peptides in gastric aspirate of preterm infant.
- FIG. 7D is a mass spectrum of the phosphopeptides in the same sample adsorbed on Sepharose-TED-Fe(III).
- FIG. 8 (bottom) is a mass spectrum of rabbit anti-human lactoferrin immunoglobin affinity adsorbed on paramagnetic Dynabead-sheep anti-rabbit IgG.
- FIG. 8 (top) is a mass spectrum of human lactoferrin and rabbit anti-human lactoferrin IgG complex affinity adsorbed on paramagmetic Dynabead-sheep anti-rabbit IgG.
- FIG. 9 is a mass spectrum of human lactoferrin affinity adsorbed on a single bead of agarose-single-stranded DNA deposited on a 0.5 mm diameter steel probe tip.
- FIG. 10 is the mass spectrum of human lactoferrin affinity adsorbed from urine on agarose-single-stranded DNA.
- FIG. 11A is a mass spectrum of human gastrointestinal fluid.
- FIG. 11B is a mass spectrum of trypsin in the same sample affinity adsorbed on AffiGel 10-soybean trypsin inhibitor.
- FIG. 12A is a mass spectrum of human serum proteins.
- FIG. 12B is a mass spectrum of human serum albumin in the same sample affinity adsorbed on agarose-Cibacron blue.
- FIG. 13 is a drawing of the surface bound cinnamamide; R represents the surface plus cross-linear.
- FIG. 14A is a mass spectrum of peptide mixtures on surface bound cinnamamide.
- FIG. 14B shows the mass spectrum of the same peptide mixtures on free cinnamamide.
- FIG. 15 is a drawing of the surface bound cinnamyl bromide; tvo structural forms are possible; R represents the surface plus cross-linear.
- FIG. 16A is a mass spectrum of peptide mixtures on surface bound cinnamyl bromide.
- FIG. 16B is a mass spectrum of the same peptide mixtures on free cinnamyl bromide.
- FIG. 17 is a drawing of the surface bound MAP-dihydroxybenzoic acid; R represents the surface plus cross-linear.
- FIG. 18 is a mass spectrum of peptide mixtures on surface bound MAP alone (control surface).
- FIG. 18B is a mass spectrum of the same peptide mixtures on surface bound MAP-dihydroxybenzoic acid.
- FIG. 19A is a mass spectrum of myoglobin on surface bound cyanohydroxycinnamic acid.
- FIG. 19B is the same mass spectrum in the low mass region.
- Sinapinic acid (dimethoxy hydroxycinnamic acid) (Aldrich Chemical Co., Inc., Milwaukee, Wis.) 20 mg/ml water suspension (intrinsic pH 3.88) Dihydoxybenzoic acid (Aldrich) 20 mg/ml water (intrinsic pH 2.07) Cyanohydroxycinnamic acid (Aldrich) 20 mg/ml water suspension (intrinsic pH 3.3) each titrated with triethylamine (Pierce, Rockford, Ill.) to pH 6.5, 7.2 and 6.5 respectively
- FIG. 1 showed the in situ metal-binding properties of the peptides under neutralized condition.
- Solid glass rod (1.5 mm dia) was cut into 1 cm segments and inserted into stainless steel probe tip support
- Cu(II) was chelated by iminodiacetate group covalently attached to either porous agarose beads (Chelating Sepharose Fast Flow, Pharmacia Biotech Inc., Piscataway, N.J., ligand density 22-30 umole/ml gel) or solid TSK-SW beads (ToyoSoda, Japan, ligand density 20 umole/ml gel)
- Fe(III) was chelated by tris(carboxymethyl)ethylenediamine-Sepharose 6B (synthesized as described by Yip and Hutchens, Protein Expression and Purification 2(1991)355-362, ligand density 65 umole/ml)
- FIG. 5A showed the molecular ions (and multiple Na-adducts) of neurotensin and sperm activating factor which were not adsorbed by the IDA-Cu(II).
- the mass spectrum in FIG. 5B showed mainly the angiotensin I plus Na-adducts.
- the IDA-Cu(II) gel was further washed with 500 ul of water 2 ⁇ , the resulting mass spectrum showed only the parent angiotensin I species with no other adduct peaks.
- Polyclonal rabbit anti-human lactoferrin antibody was custom generated for this lab by Bethyl Laboratories (Montgomery, Tex.). It was purified by thiophilic adsorption and then by immobilized lactoferrin column. Sheep anti-rabbit IgG covalently attached to magnetic beads were obtained from Dynal AS (Oslo, Norway) (uniform 2.8 um superparamagnetic polystyrene beads, ligand density 10 ug sheep IgG per mg bead).
- Cibacron Blue 3GA-agarose (Type 3000, 4% beaded agarose, ligand density 2-5 umoles/ml, Sigma).
- Other immobilized dyes include Reactive Red 120-agarose, Reactive Blue-agarose, Reactive Green-agarose, Reactive Yellow-agarose (Sigma)
- Cinnamamide (Aldrich, not a matrix by prior art) was dissolved in isopropanol/0.5 M sodium carbonate (3:1) and mixed with divinyl sulfone (Fluka, Ronkonkoma, N.Y.) activated Sepharose (Pharmacia) at room temperature for 2 hr. The excess molecules were washed away with isopropanol.
- the proposed structure was presented in FIG. 13. 2 ul of bound or free molecule was deposited on the probe tips, 1 ul of peptide mixtures in 0.1% TFA was added on top and the result showed the peptide ion signals detected only for the bound form.
- Group 4 Energy Absorbing Molecule Covalently Bonded to Surface via Undetermined Group.
- Cyanohydroxycinnamic acid was dissolved in methanol and mixed with AffiGel 10 (BioRad) at room temperature for two hours. The unbound molecules were washed away with methanol. Protein samples that are found to desorb successfully from this modified surface include myoglobin (FIG. 19), trypsin and carbonic anhydrase.
- Presenting surface the probe tip, sample plate or other surface on which the analyte and matrix are presented for desorption/ionization and analysis for example by mass spectrometry.
- “Matrix” as described in prior art as the substance mixed with the analyte (typically prior to deposition) and deposited on the presenting surface in association with the analyte to absorb at least part of the energy from the energy source (e.g., laser) to facilitate desorption of intact molecules of the analyte.
- the energy source e.g., laser
- “Affinity reagent” analyte capture device—the class of molecules (both man made, unnatural, natural and biological) and/or compounds which have the ability of being retained on the presenting surface (by covalent bonding, chemical absorption, etc.) while retaining the ability of recognition and bonding to an analyte.
- Adduct the appearance of an additional mass associated with the analyte and usually caused by the reaction of excess matrix (or matrix break-down products) directly with the analyte.
- “Adsorption” the chemical bonding (covalent and/or noncovalent) of the energy-absorbing molecules, the affinity reagent (i.e., analyte capture device), and/or the analyte to the probe (presenting surface).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Analytical Chemistry (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Electron Tubes For Measurement (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Photoreceptors In Electrophotography (AREA)
Abstract
This invention relates generally to methods and apparatus for desorption and ionization of analytes for the purpose of subsequent scientific analysis by such methods, for example, as mass spectrometry or biosensors. More specifically, this invention relates to the field of mass spectrometry, especially to the type of matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry used to analyze macromolecules, such as proteins or biomolecules. Most specifically, this invention relates to the sample probe geometry, sample probe composition, and sample probe surface chemistries that enable the selective capture and desorption of analytes, including intact macromolecules, directly from the probe surface into the gas (vapor) phase without added chemical matrix.
Description
- [0001] The United States government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Grant No. 58-6250-1-003 awarded by the United States Department of Agriculture.
- 1. Field of the Invention.
- This invention relates generally to methods and apparatus for desorption and ionization of analytes for the purpose of subsequent scientific analysis by such methods, for example, as mass spectrometry or biosensors. More specifically, this invention relates to the field of mass spectrometry, especially to the type of matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry used to analyze macromolecules, such as proteins or biomolecules.
- 2. Description of the Prior Art.
- Generally, analysis by mass spectrometry involves the vaporization and ionization of a small sample of material, using a high energy source, such as a laser, including a laser beam. The material is vaporized from the surface of a probe tip by the laser beam, and in the process, some of the individual molecules are ionized by the gain of a proton. The positively charged ionized molecules are then accelerated through a short high voltage field and let fly into a high vacuum chamber, at the far end of which they strike a sensitive detector surface. Since the time of flight is a function of the mass of the ionized molecule, the elapsed time between ionization and impact can be used to determine the molecule's mass which, in turn, can be used to identify the presence or absence of known molecules of specific mass.
- All known prior art procedures which present proteins or other large biomolecules on a probe tip for laser desorption/ionization time-of-flight mass spectrometry rely on a crystalline solid mixture of the protein or other analyte molecule in a large excess of acidic matrix material deposited on the bare surface of a metallic probe tip. (The sample probe tip typically is metallic, either stainless steel, nickel plated material or platinum). Immobilizing the analyte in such a matrix was thought to be necessary in order to prevent the destruction of analyte molecules by the laser beam. The laser beam strikes the mixture on the probe tip and its energy is used to vaporize a small portion of the matrix material along with some of the embedded analyte molecules. Without the matrix, the analyte molecules are easily fragmented by the laser energy, so that the mass, and identity, of the original macromolecule is very difficult to determine.
- This prior art procedure has several limitations which have prevented its adaptation to automated protein or other macrobiological molecules analysis. First, in a very crude sample it is necessary to partially fractionate (or otherwise purify the sample as much as possible) to eliminate the-presence of excessive extraneous materials in the matrix/analyte crystalline mixture. The presence of large quantities of components may depress the signal of the targeted analyte. Such purification is time-consuming and expensive and would be very difficult to do in an automated analyzer.
- Second, while the amount of analyte material needed for analysis by the prior art method is not large (typically in a picomole range), in some circumstances, such as tests on pediatric patients, analyte fluids are available only in extremely small volumes (microliters) and may be needed for performing several different analyses. Therefore, even the small amount needed for preparation of the analyte/matrix crystalline mixture for a single analysis may be significant. Also, only a tiny fraction (a few thousandths or less) of analyte used in preparing the analyte/matrix mixture for use on the probe tip is actually consumed in the mass spectrometry analysis. Any improvement in the prior art procedure which made it possible to use much less analyte to conduct the test would be highly advantageous in many clinical areas.
- Third, the analyte protein, or other macromolecule, used in preparing the analyte matrix for use on the probe tip is not suitable for any subsequent chemical tests or procedures because it is bound up in the matrix material. Also, all of the matrix material used to date is strongly acidic, so that it would affect many chemical reactions which might be attempted on the mixture in order to modify the analyte molecules for subsequent examination. Any improvement in the procedure which made it possible to conduct subsequent chemical modifications or reactions on the analyte molecules, without removing them from the matrix or the probe tip, would be of enormous benefit to researchers and clinicians.
- Additional limitations in the prior art included problems with matrix use such as:
- (1) formation of analyte-matrix complex (referred to as “matrix adduct” which interferes with the accuracy of analyte measurement;
- (2) inability to wash away contaminants present in analyte or matrix (e.g., other proteins or salts);
- (3) formation of analyte-salt ion adducts;
- (4) less than optimum solubility of analyte in matrix;
- (5) signal (molecular ion) suppression “poisoning” due to simultaneous presence of multiple components; and
- (6) selective analyte desorption/ionization.
- There are a number of problems and limitations with the prior art methods. Prior investigators, including Karas and Hillenkamp have reported a variety of techniques for analyte detection using mass spectroscopy, but these techniques suffered because of inherent limitations in sensitivity and selectivity of the techniques, specifically including limitations in detection of analytes in low volume, undifferentiated samples. The “Hillenkamp-Karas” articles that pertain to this field of invention are:
- 1. Hillenkamp, “Laser Desorption Mass Spectrometry: Mechanisms, Techniques and Applications”;Bordeaux Mass Spectrometry Conference Report, 1988, pages 354-362.
- 2. Karas and Hillenkamp, “Ultraviolet Laser Desorption of Proteins Up to 120,000 Daltons”,Bordeaux Mass Spectrometry Conference Report, 1988, pages 416, 417.
- 3. Karas and Hillenkamp, “Laser Desorption Ionization of Proteins With Molecular Masses Exceeding 10,000 Daltons”,Analytical Chemistry, 60. 2299, July 1988.
- 4. Karas, Ingendoh, Bahr and Hillenkamp, “UV-Laser Desorption/Ionization Mass Spectrometry of Femtomol Amounts of Large Proteins”,Biomed. Environ. Mass Spectrum (in press).
- The use of laser beams in time-of-flight mass spectrometers is shown, for example, in U.S. Pat. Nos. 4,694,167; 4,686,366, 4,295,046, and 5,045,694, incorporated by reference.
- The first successful molecular mass measurements of intact peptides and small proteins (only up to about 15 kDa) by any form of mass spectrometry were made by bombarding surfaces with high energy particles (plasma desorption and fast atom bombardment mass spectrometry); this breakthrough came in 1981 and 1982. Improvements came in 1985 and 1986, however, yield (signal intensities), sensitivity, precision, and mass accuracy remained relatively low. Higher molecular mass proteins (about 20 to 25 kDa) were not observed except on rare occasions; proteins representing average molecular weights (approximately 70 kDa) were not ever observed with these methods. Thus, evaluation of most proteins by mass spectrometry remains unrealized.
- In 1988, Hillenkamp and his coworkers used UV laser desorption time-of-flight mass spectrometry and discovered that when proteins of relatively high molecular mass were deposited on the probe tip in the presence of a very large molar excess of an acidic, UV absorbing chemical matrix (nicotinic acid) they could be desorbed in the intact state. This new technique is called matrix-assisted laser desorption/ionization (MALDI) time-of-flight mass spectrometry. Note that laser desorption time-of-flight mass spectrometry (without the chemical matrix) had been around for some time, however, there was little or no success determining the molecular weights of large intact biopolymers such as proteins and nucleic acids because they were fragmented (destroyed) upon desorption. Thus, prior to the introduction of a chemical matrix, laser desorption mass spectrometry was essentially useless for the detection of specific changes in the mass of intact macromolecules (see below). Note that the random formation of matrix crystals and the random inclusion of analyte molecules in the solid solution is prior art.
- The primary object of the invention is to provide improved methods, materials composition and apparatus for coupled adsorption, desorption and ionization of multiple or selected analytes into the gas (vapor) phase, preferably for use in conjunction with mass spectrometry of biomolecules and other macromolecules, as well as by means of analytic detection other than mass spectrometry. The invention incudes a flexible variety of options for presenting surfaces with attached energy absorbing molecules, defined reaction sites, and affinity reagents for the capture,e transfer, and/or the desorption of analytes before and after a sseries of chemical, physical, and/or enzymatic modifications performed in situ.
- Another object is to provide such a method and apparatus for affinity-directed detection of analytes, including desorption and ionization of analytes in which the analyte is not dispersed in a matrix solution or crystalline structure but is presented within, on or above an attached surface of energy absorbing “matrix” material through molecular recognition events, in a position where it is accessible and amenable to a wide variety of chemical, physical and biological modification or recognition reactions.
- The probe surface with and without bonded energy absorbing molecules, referred to as the sample presenting surface can be composed of a variety of materials, including porous or nonporous materials, with the porous materials providing sponge-like, polymeric, high surface areas for optimized adsorption and presentation of analyte.
- These surface materials can be substituted (at varying densities) with chemically bonded (covalent or noncovalent) affinity adsorption reagents and/or chemically bonded (i.e., immobilized) energy absorbing molecules (bound “matrix” molecules). The geometry of the sample presenting surface can be varied (i.e., size, texture, flexibility, thickness, etc.) to suit the need (e.g., insertion into a living organism through spaces of predetermined sizes) of the experiment (assay).
- Another object is to provide such a method and apparatus in which the analyte material is chemically bound or physically adhered to a substrate forming a probe tip or other sample presenting surface.
- A further object is to provide means for the modification of probe or sample presenting surfaces with energy-absorbing molecules to enable the successful desorption of analyte molecules without the addition of exogenous matrix molecules as in prior art.
- A further object is to provide the appropriate density of energy-absorbing molecules bonded (covalently or noncovalently) in a variety of geometries such that mono layers and multiple layers of attached energy-absorbing molecules can be used to facilitate the desorption of analyte molecules of varying masses. The optimum ratio of adsorbed or bonded energy-absorbing molecules to analyte varies with the mass of the analyte to be detected. A further object is to modify the sample presenting surface with such energy-absorbing molecules where the composition of the probe or sample presenting surface is other than the metal or metallic surfaces as described in prior art. Separate from the chemical and/or physical modification of the probe surface with energy absorbing molecules is the modification-of-these surfaces with affinity reagents, both chemical and/or biological, for the specific purpose of capturing (adsorbing) specific analyte molecules or classes of analyte molecules for the subsequent preparation, modification, and successful desorption of said analyte molecules.
- A further object is to provide all combinations of surfaces modified with energy-absorbing molecules and/or affinity-directed analyte capture devices to enable the selective and/or nonselective adsorption of analytes and the subsequent desorption either with or without requiring the subsequent addition of additional matrix molecules. It is important to note that the surfaces modified with affinity reagents for the capture of analytes are-more useful than the underivitized sample surfaces described in prior art even when the deposition of energy-absorbing molecules (that is matrix) is as described in prior art. Because of the advantages in the ability to remove contaminating substances from the adsorbed analyte molecules and because of the ability to modify adsorbed analyte molecules without (or before) added matrix.
- A further object is to provide such a method and apparatus in which the substrate forming the probe tip or other sample presenting surface is derivatized with one or more affinity reagents (a variety of densities and degrees of amplification) for selective bonding with predetermined analytes or classes of analytes.
- A further object is to provide methods and apparatus for using probe tips having surfaces derivatized with affinity reagents and containing laser desorption matrix material (chemically bonded to surface or not) which may be used to isolate target analyte materials from undifferentiated biological samples such as blood, tears, urine, saliva, gastrointestinal fluids, spinal fluid, amniotic fluid, bone marrow, bacteria, viruses, cells in culture, biopsy tissue, plant tissue or fluids, insect tissue or fluids, etc.
- Because of the new and preferred method for presentation and desorption of selected analytes, a further object is to use analyte detection methods other than the generic electron multipliers typically used in mass spectrometric devices. This would include but would not be limited to detection films/plates for the qualitative or quantitative evaluation of fluorescent or radio-labeled anialytes or analyte molecule complexes.
- A further object is to provide such a system in which the affinity reagent chemically bonds or biologically adheres to the target analyte or class of analytes.
- A further object is to use existing and new solid phase affinity reagents (e.g., small diameter porous or nonporous beads of crosslineated polymer with attached molecular capture devices) designed for the (1) capture (adsorption of one or more analytes, (2) the preparation of these captured analytes (e.g., washing with H2O or other buffered or nonbuffered solutions to remove contaminants such as salts, multiple cycles of washing, such as with polar organic solvent, detergent-dissolving solvent, dilute acid, dilute base or urea), and (3) most importantly, the direct transfer of these captured and prepared analytes to the probe surface for subsequent analyte desorption (for detection, quantification and/or mass analysis).
- A further object is to provide such a system in which the predetermined analytes are individual biomolecules or other macromolecules or combinations of adjoined molecules (i.e., complexes).
- A still further object is to provide such a method and apparatus in which the matrix materials used are not strongly acidic, as in prior art matrices, but are chemically modified into the slightly acidic, neutral pH or strongly basic range of pH.
- A further object is to provide such a system in which the matrix material has a pH above 6.0.
- A still further object is to provide a method and apparatus for desorption and ionization of analytes in which unused portion of the analytes contained on the presenting surface remain chemically accessible, so that a series of chemical and/or enzymatic or other treatments (e.g., discovery of analyte-associated molecules by molecular recognition) of the analyte may be conducted on the probe tip or other presenting surface, in situ, followed by sequential analyses of the modified analyte by mass spectrometry. In one case (i.e., repetitive sequential analyses) the analyte is adsorbed to the sample presenting surface and can be treated (modified in situ after the excess free matrix is removed (i.e., washed away). Matrix can be added back before analysis by mass spectrometry. Using this procedure, an analyte can be repeatedly tested for a variety of components by removing one matrix, modifying the analyte sample, re-applying the same or different matrix, analyzing the sample, etc.
- A further object is to provide a method and apparatus for the combined chemical and/or enzymatic modifications of target analytes for the purpose of elucidating primary, secondary, tertiary, or quaternary structure of the analyte and its components.
- A still further object is to provide such a method and apparatus in which the probe tips or other sample presenting surfaces are formed of a variety of materials, including electrically insulating materials (porous and nonporous), flexible or nonrigid materials, optically transparent materials (e.g., glass, including glass of varying densities, thicknesses, colors and with varying refractive indices), as well as less reactive, more biocompatible materials (e.g., biopolymers such as agarose, dextran, cellulose, starches, peptides, and fragments of proteins and of nucleic acids such as DNA (deoxyribonucleic acid) and RNA (ribonucleic acid). These surfaces can be chemically modified by the attachment of energy-absorbing molecules and/or affinity directed analyte capture molecules.
- Another object is to provide a method and apparatus for desorption and ionization of analyte materials in which cations other than protons (H+) are utilized for ionization of analyte macromolecules.
- Note that the laser or light source used to convey energy to the probe surface can employ a wavelength(s) that is(are) not fixed but can be varied according to the wavelength absorbed by the matrix (whether the matrix is added in the free form or is chemically bonded to the probe (sample presenting) surface). For this procedure, a variety of wavelengths (10 or more) defined by absorbance of matrix or energy absorbing surface can be utilized.
- Another object is to provide such a method and apparatus in which the probe tips or other sample presenting surfaces used for laser desorption/ionization time-of-flight mass spectrometry are magnetized and in which the matrix, affinity directed absorption molecules and/or analyte materials are magnetically adhered to such magnetized surface.
- A further object is a method and apparatus in which the matrix and/or analyte materials are adhered by any variety of chemical mechanisms to the sample presenting surface.
- A further objective is to provide energy-absorbing molecules which have been incorporated into other chemical structures (e.g., chemical or biological polymers) for the deposition (covalent or noncovalent) onto the sample presenting surface in a way that enables repetitious analyte desorption events without interference with chemical and/or enzymatic modifications of the analyte molecule(s) performed in situ.
- Another object is to provide sample presenting surfaces in a variety of sizes and configurations (up to 4“×4”) with multiple (up to 10,000 or more) spots (including spots down to <0.001 inch diameter) of affinity reagents arranged in predetermined arrays for the selective adsorption of numerous different analytes (e.g., clinical chemical marker proteins) to enable a wide spectrum sampling of the macromolecular composition of biological samples/fluids.
- As shown more fully below, the present invention overcomes limitations and disabilities of the prior art by providing probe tips or sample plates whose surfaces have been derivatized with biospecific affinity reagents which will selectively bind specific groups or types of biomolecules or other analytes out of an undifferentiated sample (such as blood or urine). Appropriate selection of the affinity reagents used to derivatize the probe tip surface therefore makes possible the selection from the undifferentiated sample and binding to the probe tip of the specific types or groups of biological or other macromolecules under investigation, or subsequent examination (e.g., quantification and/or structure elucidation) by mass spectrometry. This has the advantage of achieving both the purification of the analyte sample previously required and the effect of concentrating the analyte. It reduces by a factor of 1,000 to 100,000 the amount of analyte needed for the mass spectrometry examination, since only the macromolecules which attach to the biospecific affinity reagents are removed from the analyte sample, and these can be sequestered on predetermined areas of the probe tips or sample plates that are even less than the laser spot size.
- It also has been found that the probe tips used in the process of the invention need not be metal or metal-coated, as with prior art procedures. Research involved in the invention has involved glass and synthetic polymer surfaces such as polystyrene, polypropylene, polyethylene, polycarbonate and other polymers including biopolymers, for the probe tips which have been covalently or noncovalently derivatized for immobilization of specific reagents that will direct the selective adsorption of specific analytes. These surfaces will include immobilized metal ions, immobilized proteins, peptides, enzymes, and inhibitor molecules, immobilized DNA and RNA, immobilized antibodies, immobilized reducing agents, immobilized carbohydrates and lectins, immobilized dyes and immobilized protein surface domains involved in molecular recognition (e.g., dimerization domains and subunits). Some of the chemical and surface structures are as yet unknowvn.
- The preferred probe tip, or sample plate, for selective adsorption/presentation of sample for mass analysis are (1) stainless steel (or other metal) with a synthetic polymer coating (e.g., cross-linked dextran or agarose, nylon, polyethylene, polystyrene) suitable for covalent attachment of specific biomolecules or other nonbiological affinity reagents, (2) glass or ceramic, and/or (3) plastic (synthetic polymer). The chemical structures involved in the selective immobilization of affinity reagents to these probe surfaces will encompass the known variety of oxygen-dependent, carbon-dependent, sulfur-dependent, and/or nitrogen-dependent means of covalent or noncovalent immobilization. The methods and chemical reactions used in producing such surfaces derivatized with biospecific affinity reagents already are known by those skilled in the art. Two features of the invention, however, are (1) the specific size and localization of the derivatized surface with respect to the laser beam and (2) the affinity directed presentation of specific analyte molecules (e.g., macromolecule or biopolymer) at a defined surface density or local concentration required for the efficient detection by laser desorption/ionization time-of-flight mass spectrometry. This can be accomplished by arranging the affinity adsorption “spots” (0.005 to 0.080 inch diameter) on the probe surface in a defined manner (400 to 1,000 spots could be placed on a surface about the size of a glass slide).
- An additional discovery involves the fact that pH modified chemical matrices can be used on these surfaces to facilitate desorption/ionization without disruption of conditions necessary for subsequent sample modification. As discussed above, prior art matrix materials used for biomolecular mass spectrometry are acidic. The exact chemical structure of the pH-modified matrices still are unknown. However, by suitable neutralization of the matrix material, it can be made largely passive to subsequent chemical or enzymatic reactions carried out on the analyte molecules presented on the derivatized probe tip surface by the biospecific affinity reagents. This makes possible the carrying out of chemical reactions on the analyte molecules presented on the probe tips. Since only a small fraction of the analyte molecules are used in each desorption/mass spectrometer measurement, a number of sequential chemical and/or enzymatic modifications of the samples, in situ, on the probe tips, and subsequent analysis of the modified samples by mass spectrometry, can be carried out on the same probe tips in order to more accurately determine exactly what molecule is present, or other characteristics or information about the molecule, including its structure.
- Finally, even when these matrix molecules are immobilized on a probe tip surface, the analyte deposited on such a surface can be desorbed with a laser beam. This circumvents the contamination of the analyte by the matrix molecules. As a particular feature of the invention, we have shown that some energy absorbing molecules that do not work as “matrix” molecules when added to analytes as a solution of free molecules (as in prior art) do indeed work well to facilitate the desorption of intact analyte molecules after being immobilized.
- It seems likely that these improvements in the procedure will enable bioanalytical and medical instrument manufacturers to develop a machine for the automated evaluation of a single protein sample deposited on a surface and modified with numerous chemical and/or enzymatic reactions performed in situ.
- The foregoing and other objects and advantages of the invention will be apparent from the following specification and from the accompanying drawings.
- FIG. 1A is a mass spectrum of peptide mixtures using sinapinic acid pH 6.5 as the matrix. FIG. 1B is a mass spectrum of the same peptide mixtures after in situ addition of CuSO4.
- FIG. 2A is a mass spectrum of human casein phosphopeptide (R1-K18+5P) using sinapinic acid pH 6.5 as the matrix. FIG. 2B shows the mass spectrum of the same peptide after in situ alkaline phosphatase digestion for 5 and 10 min respectively. FIG. 2D shows the mass spectrum of the same peptide using dihydroxybenzoic acid pH 2 as the matrix, after in situ alkaline phosphatase digestion for 10 min.
- FIG. 3 is a mass spectrum histidine-rich glycoprotein (GHHPH)5G peptide using sinapinic acid pH 6.2 as the matrix before and after in situ digestion with carboxypeptidase P.
- FIG. 4 is a composite mass spectra of peptide mixtures using sinapinic acid as the matrix on glass, polypropylene-coated steel, polystyrene-coated steel and nylon probe tips.
- FIG. 5A is a mass spectrum of peptides unadsorbed by TSK SW-IDA-Cu(II). FIG. 5B is a mass spectrum of peptide adsorbed by TSK SW-IDA-Cu(II). FIG. 5C is a mass spectrum of the same peptide adsorbed on TSK SW-IDA-Cu(II) after water wash.
- FIG. 6 is a mass spectrum of myoglobin (<8 fmole) affinity-adsorbed on TSK SW-IDA-Cu(II).
- FIG. 7A is a mass spectrum of proteins/peptides in infant formula. FIG. 7B is a mass spectrum of phosphopeptides in the same sample affinity-adsorbed on Sepharose-TED-Fe(III). FIG. 7C is a mass spectrum of proteins/peptides in gastric aspirate of preterm infant. FIG. 7D is a mass spectrum of the phosphopeptides in the same sample adsorbed on Sepharose-TED-Fe(III).
- FIG. 8 (bottom) is a mass spectrum of rabbit anti-human lactoferrin immunoglobin affinity adsorbed on paramagnetic Dynabead-sheep anti-rabbit IgG. FIG. 8 (top) is a mass spectrum of human lactoferrin and rabbit anti-human lactoferrin IgG complex affinity adsorbed on paramagmetic Dynabead-sheep anti-rabbit IgG.
- FIG. 9 is a mass spectrum of human lactoferrin affinity adsorbed on a single bead of agarose-single-stranded DNA deposited on a 0.5 mm diameter steel probe tip.
- FIG. 10 is the mass spectrum of human lactoferrin affinity adsorbed from urine on agarose-single-stranded DNA.
- FIG. 11A is a mass spectrum of human gastrointestinal fluid. FIG. 11B is a mass spectrum of trypsin in the same sample affinity adsorbed on AffiGel 10-soybean trypsin inhibitor.
- FIG. 12A is a mass spectrum of human serum proteins. FIG. 12B is a mass spectrum of human serum albumin in the same sample affinity adsorbed on agarose-Cibacron blue.
- FIG. 13 is a drawing of the surface bound cinnamamide; R represents the surface plus cross-linear.
- FIG. 14A is a mass spectrum of peptide mixtures on surface bound cinnamamide. FIG. 14B shows the mass spectrum of the same peptide mixtures on free cinnamamide.
- FIG. 15 is a drawing of the surface bound cinnamyl bromide; tvo structural forms are possible; R represents the surface plus cross-linear.
- FIG. 16A is a mass spectrum of peptide mixtures on surface bound cinnamyl bromide. FIG. 16B is a mass spectrum of the same peptide mixtures on free cinnamyl bromide.
- FIG. 17 is a drawing of the surface bound MAP-dihydroxybenzoic acid; R represents the surface plus cross-linear.
- FIG. 18 is a mass spectrum of peptide mixtures on surface bound MAP alone (control surface). FIG. 18B is a mass spectrum of the same peptide mixtures on surface bound MAP-dihydroxybenzoic acid.
- FIG. 19A is a mass spectrum of myoglobin on surface bound cyanohydroxycinnamic acid. FIG. 19B is the same mass spectrum in the low mass region.
- Usage of Conventional Matrix in Aqueous, pH-neutralized Form
- Sinapinic acid (dimethoxy hydroxycinnamic acid) (Aldrich Chemical Co., Inc., Milwaukee, Wis.) 20 mg/ml water suspension (intrinsic pH 3.88) Dihydoxybenzoic acid (Aldrich) 20 mg/ml water (intrinsic pH 2.07) Cyanohydroxycinnamic acid (Aldrich) 20 mg/ml water suspension (intrinsic pH 3.3) each titrated with triethylamine (Pierce, Rockford, Ill.) to pH 6.5, 7.2 and 6.5 respectively
- 2 ul of the matrix solution was mixed with 1 ul of sample and allowed to air dry
- 1. A mixture of synthetic peptides-human histidine-rich glycoprotein peptide (GHHPH)2G, (GHHPH)5G, human estrogen receptor dimerization domain (D473-L525) with neutralized sinapinic acid as the matrix, in the absence and presence of Cu(II). FIG. 1 showed the in situ metal-binding properties of the peptides under neutralized condition.
- 2. Casein phosphopeptide (R1-K18+5P) with sinapinic acid pH 6.5. Followed by in situ alkaline phosphatase (0.5 ul, Sigma) digestion for 10 min at room temperature. Similar in situ digestion on the same peptide with dihydoxybenzoic acid (prepared in 30% methanol/0.1% trifluoroacetic acid) was used as control. FIG. 2 showed the more efficient enzymatic dephosphorylation under neutralized condition.
- 3. Mixture of synthetic peptides as in 1 with sinapinic acid pH 6.2, followed by in situ carboxypeptidase P (1 ul, Boehringer Mannheim Corp, Indianapolis, Id., 20 ug/50 ul) digestion for 30 min at room temperature. FIG. 3 showed preferential removal of C-terminal amino acid from histidine-rich glycoprotein peptide. Also showed unambiguous C-terminal determination even in peptide mixtures.
- Usage of Probe Tip (Surface) Materials (Composition) other than Stainless Steel or Platinum for Sample Deposition
- Molten polypropylene or polystyrene was deposited on stainless steel probe tip so as to cover it completely
- Solid glass rod (1.5 mm dia) was cut into 1 cm segments and inserted into stainless steel probe tip support
- Solid nylon (Trimmer line, 1.5 mm dia, Arnold, Shelby, Ohio) was cut into 1 cm segments and inserted into stainless steel probe tip support
- Magnetic stir. bars (1.5×8 mm, teflon coated, Curtin Matheson Scientific, Inc., Houston Tex.) inserted into stainless steel probe tip support
- Peptide mixtures (as in FIG. 1 with dihydroxybenzoic acid in 30% methanol/0.1% TFA) on all four surfaces. FIG. 4
- Affinity-directed Laser Desorption (with Matrix Added as Described in Prior Art)
-
Group 1. Immobilized Metal Ion as the Affinity Ligand - Cu(II) was chelated by iminodiacetate group covalently attached to either porous agarose beads (Chelating Sepharose Fast Flow, Pharmacia Biotech Inc., Piscataway, N.J., ligand density 22-30 umole/ml gel) or solid TSK-SW beads (ToyoSoda, Japan,
ligand density 20 umole/ml gel) - Fe(III) was chelated by tris(carboxymethyl)ethylenediamine-Sepharose 6B (synthesized as described by Yip and Hutchens, Protein Expression and Purification 2(1991)355-362, ligand density 65 umole/ml)
- 1. A mixture of synthetic peptides, neurotensin (30 nmole), sperm activating peptide (50 nmole) and angiotensin I (150 nmole), were mixed with 50 ul packed volume of TSK SW-IDA-Cu(II) at pH 7.0 (20 mM sodium phosphate, 0.5 M NaCI) at room temperature for 10 min. The gel was then washed with 3×200 ul sodium phosphate buffer, containing 0.5 M NaCl, pH 7.0 and suspended in equal volume of water. 2 ul of the gel suspension was mixed with 1 ul sinapinic acid (methanol). FIG. 5A showed the molecular ions (and multiple Na-adducts) of neurotensin and sperm activating factor which were not adsorbed by the IDA-Cu(II). The mass spectrum in FIG. 5B showed mainly the angiotensin I plus Na-adducts. When the IDA-Cu(II) gel was further washed with 500 ul of water 2×, the resulting mass spectrum showed only the parent angiotensin I species with no other adduct peaks. When the IDA-Cu(II) gel beads with adsorbed angiotensin was incubated with cyanohydroxycinnamic acid (20 mg/ml water) pH 7.0 for 10 min at room temperature and then analyzed separately, the angiotensin I was found to be still associated with the gel beads and not with the matrix solution.
- 2. Horse heart myoglobin (325 pmole) was mixed with 50 ul of TSK SW-IDA-Cu(II) gel beads in 20 mM sodium phosphate, 0.5 M NaCl, pH 7.0 at room temperature for 10 min. The gel beads were then washed with 2×500 ul of buffer and 2×500 ul of water. The beads were suspended in equal volume of water and then serial diluted into water. 0.5 ul of the diluted gel suspension was mixed with 1 ul of sinapinic acid (30% methanol/0.1% TFA). A detectable signal (after averaging 50 laser shots) of myoglobin was still obtained when the calculated quantity equivalent to or less than 8 fmole was deposited on the probe tip. FIG. 6
- 3. 100 ul of infant formula and gastric content of preterm infant aspirated 90 min after feeding of infant formula was mixed with 50 ul of TED-Fe(III) in 0.1 M MES, 0.15 M NaCl, pH 6.5 at room temperature for 15 min. The gel beads were then washed with 3×500 ul of MES buffer and then with 1×500 ul of water. 1 ul of the gel suspension was mixed with 2 ul of sinapinic acid (50% acetonitrile/0.1% TFA). The result showed that gastric aspirate had much more low molecular weight phosphopeptides (i.e., bound by TED-Fe(III)) than the formula due to proteolytic digestion. In situ alkaline phosphatase digestion of peptides adsorbed on the TED-Fe(III) gel beads showed shifts to lower molecular weight indicating that they are indeed phosphopeptides. FIG. 7
- Group 2. Immobilized Antibody as the Affinity Ligand
- Polyclonal rabbit anti-human lactoferrin antibody was custom generated for this lab by Bethyl Laboratories (Montgomery, Tex.). It was purified by thiophilic adsorption and then by immobilized lactoferrin column. Sheep anti-rabbit IgG covalently attached to magnetic beads were obtained from Dynal AS (Oslo, Norway) (uniform 2.8 um superparamagnetic polystyrene beads,
ligand density 10 ug sheep IgG per mg bead). - 1. Human lactoferrin (1 nmole) was incubated with rabbit antihuman lactoferrin at 37° for 30 min. Subsequently, 40 ul of sheep anti-rabbit IgG on Dynabeads (6-7×108 beads/ml) was added and incubated at 37° for 30 min. The beads were then washed with 3×500 ul of sodium phosphate buffer, and 2×500 ul of water. The final amount of human lactoferrin bound to the complex was estimated to be 4 pmole. Approximately {fraction (1/10 )} of the beads was transferred to a magnetic probe tip and mixed with 2 ul of sinapinic acid (30% MeOH/0.1% TFA). Result showed the lactoferrin ion signal in addition to the rabbit IgG signal. FIG. 8
-
Group 3. Immobilized Nucleic Acid as the Affinity Ligand - Single-strand DNA immobilized on 4% agarose beads was obtained from GIBCO BRL, Gaithersburg, Md. The ligand density was 0.5-1.0 mg/ml.
- 1. 200 ul of125I human lactoferrin (equivalent to 49 nmole) was mixed with 100 ul of immobilized single-strand DNA in 20 mM HEPES, pH 7.0 at room temperature for 10 min. The beads were then washed with 5×500 ul of HEPES buffer and then suspended in equal volume of water. The amount of lactoferrin bound per bead was found to be 62 fmole by determining the radioactivity and counting the number of beads per unit volume. Various numbers of beads (from 1 to 12) were deposited on 0.5 mm diameter probe tips and mixed with 0.2 ul of sinapinic acid (30% methanol/0.1% TFA). Lactoferrin ion signals were obtained with multiple 100 laser shots on a single bead with adsorbed lactoferrin. FIG. 9
- 2. 30 pmole of59Fe-human lactoferrin was added to 1 ml of preterm infant urine and mixed with 20 ul of immobilized single-strand DNA on agarose in 0.1 M HEPES pH 7.4 at room temperature for 15 min. The beads were washed with 2×500 ul HEPES buffer, and 2×500 ul of water. The beads were then suspended in equal volume of water and 1 ul (equivalent to not more than 350 fmole as determined by radioactivity) was mixed with 1 ul sinapinic acid (30% methanol/0.1% TFA) on a probe tip. Positive lactoferrin signals were obtained for multiple 50 laser shots. FIG. 10
- Group 4. Immobilized Biomolecule as the Affinity Ligand Soybean trypsin inhibitor (Sigma, St Louis, Mo.) was immobilized on AffiGel 10 (BioRad Laboratories, Hercules, Calif., ligand density 15 umole/ml) according to manufacturer's instructions.
- 1.100 ul of human gastrointestinal aspirate was mixed with 50 ul of immobilized soybean trypsin inhibitor in 20 mM sodium phosphate, 0.5 M sodium chloride, pH 7, at room temperature for 15 min. The gel beads were then washed with 3×500 ul of phosphate buffer, and 2×500 ul of water. 1 ul of gel bead suspension was mixed with 2 ul of sinapinic acid (50% acetonitrile/0.1% TFA). Result showed the presence of trypsin and trypsinogen in the aspirate. FIG. 11
-
Group 5. Immobilized Dye as the Affinity Ligand - Cibacron Blue 3GA-agarose (
Type 3000, 4% beaded agarose, ligand density 2-5 umoles/ml, Sigma). - Other immobilized dyes include Reactive Red 120-agarose, Reactive Blue-agarose, Reactive Green-agarose, Reactive Yellow-agarose (Sigma)
- 1. 200 ul of human plasma was mixed with 50 ul of immobilized dye in 20 mM sodium phosphate, 0.5 M NaCl, pH 7.0 at room temperature for 10 min. The gel beads were then washed with 3×500 ul of phosphate buffer and 2×500 ul of water. 1 ul of gel bead suspension was mixed with 2 ul of sinapinic acid (50% acetonitrile/0.1% TFA). Result showed the selective adsorption of human serum albumin from the serum sample by Cibacron Blue. FIG. 12
- Surface-enhanced Laser Desorption
-
Group 1. Energy-absorbing Molecule Covalently Bonded to Surface via the N-group - Cinnamamide (Aldrich, not a matrix by prior art) was dissolved in isopropanol/0.5 M sodium carbonate (3:1) and mixed with divinyl sulfone (Fluka, Ronkonkoma, N.Y.) activated Sepharose (Pharmacia) at room temperature for 2 hr. The excess molecules were washed away with isopropanol. The proposed structure was presented in FIG. 13. 2 ul of bound or free molecule was deposited on the probe tips, 1 ul of peptide mixtures in 0.1% TFA was added on top and the result showed the peptide ion signals detected only for the bound form. FIG. 14.
- Group 2. Energy Absorbing Molecule Covalently Bonded to Surface via the C-group
- Cynnamyl bromide (Aldrich, not a matrix by prior art) was dissolved in isopropanol/0.5 M sodium carbonate and mixed with divinyl sulfone-activated Sepharose at room temperature overnight. The excess molecules were washed away with isopropanol. The proposed structures are presented in FIG. 15. 2 ul of the bound or free molecule was deposited on the probe tip, 1 ul of peptide mixtures in 0.1% TFA was added on top and the result showed the detection of peptide ion signal only for the bound form. FIG. 16.
-
Group 3. Energy Absorbing Molecule Covalently Bonded to Surface via the C-group - Dihydroxybenzoic acid was activated by carbodiimide and mixed with Fmoc-
MAP 8 branch resin (Applied Biosystems, Forster City, Calif.) overnight. The proposed structure was presented in FIG. 17. After washing, 1 ul of the bonded molecule on MAP or the MAP alone in 50% acetonitrile/0.1% TFA were deposited on the probe tip, 1 ul of peptide mixture was added on top, the resulting mass spectrum was presented in FIG. 21. - Group 4. Energy Absorbing Molecule Covalently Bonded to Surface via Undetermined Group.
- Cyanohydroxycinnamic acid was dissolved in methanol and mixed with AffiGel 10 (BioRad) at room temperature for two hours. The unbound molecules were washed away with methanol. Protein samples that are found to desorb successfully from this modified surface include myoglobin (FIG. 19), trypsin and carbonic anhydrase.
- These examples (Groups 1-4) are also demonstrations of combined surface-enhanced and affinity-directed desorption where the adsorbed (bonded) energy absorbing molecular also act as affinity adsorption reagents to enhance the capture of analyte molecules.
- Definitions
- (1) “Presenting surface”—the probe tip, sample plate or other surface on which the analyte and matrix are presented for desorption/ionization and analysis for example by mass spectrometry.
- (2) “Matrix”—as described in prior art as the substance mixed with the analyte (typically prior to deposition) and deposited on the presenting surface in association with the analyte to absorb at least part of the energy from the energy source (e.g., laser) to facilitate desorption of intact molecules of the analyte.
- (3) “Analyte”—the material which is the subject of desorption and investigation by mass spectrometry or other means for detection.
- (4) “Affinity reagent” (analyte capture device)—the class of molecules (both man made, unnatural, natural and biological) and/or compounds which have the ability of being retained on the presenting surface (by covalent bonding, chemical absorption, etc.) while retaining the ability of recognition and bonding to an analyte.
- (5) “Desorption”—the departure of analyte from the surface and/or the entry of the analyte into a gaseous phase.
- (6) “Ionization”—the process of creating or retaining on an analyte an electrical charge equal to plus or minus one or more electron units.
- (7) “Adduct”—the appearance of an additional mass associated with the analyte and usually caused by the reaction of excess matrix (or matrix break-down products) directly with the analyte.
- (8) “Adsorption”—the chemical bonding (covalent and/or noncovalent) of the energy-absorbing molecules, the affinity reagent (i.e., analyte capture device), and/or the analyte to the probe (presenting surface).
Claims (31)
1. An apparatus for measuring the mass of analyte molecules by means of mass spectrometry, said apparatus comprising:
a spectrometer tube;
vacuum means for applying a vacuum to the interior of said tube;
electrical potential means within the tube for applying an accelerating electrical potential to desorbed analyte molecules;
sample presenting means removably insertable into said spectrometer means, for presenting said analyte molecules in association with a matrix material for promoting desorption and ionization of said analyte molecules, said sample presenting means being adapted to present said analyte molecules on or above the surface of said matrix material, whereby at least a portion of said analyte molecules not consumed in said mass spectrometry analysis will remain accessible for subsequent chemical analytical procedures;
laser beam means for producing a laser beam directed to said analyte molecules and matrix material on said sample presenting means inserted into said spectrometer means, for imparting sufficient energy to desorb and ionize a portion of said analyte molecules on said sample presenting means; and
detector means associated with said spectrometer tube for detecting the impact of accelerated ionized analyte molecules thereon.
2. A method in mass spectrometry to measure the mass of an analyte molecule, said method comprising the steps of:
derivitizing a surface on a probe tip face with an affinity reagent having means for selectively bonding with an analyte molecule;
exposing said derivitized probe tip face to a source of said analyte molecule so as to bond said analyte molecule thereto;
placing the probe tip into one end of a time-of-flight mass spectrometer and applying a vacuum and an electric field to form an accelerating potential within the spectrometer;
striking the probe tip face within the spectrometer with a series of laser pulses in order to desorb ions of said analyte molecules from said tip;
detecting the mass weights of the ions by their time of flight within said mass spectrometer; and
displaying such detected mass weights.
3. The method according to claim 2 comprising additionally applying a desorption assisting matrix material to said probe tip face in association with said affinity reagent, said matrix material being applied in a manner so as not to interfere with said means on said affinity reagent for selectively bonding with said analyte molecules,
a portion of said analyte molecules which are not desorbed from said probe tip remaining chemically accessible for subsequent analytical procedures without the necessity for separating them from said matrix material.
4. The method according to claim 3 comprising additionally,
removing said probe tip from said mass spectrometer;
performing a chemical procedure on said portion of said analyte molecules so as to alter the chemical composition of said portion of said analyte molecules;
reinserting said probe tip with said chemically altered analyte molecules thereon; and
performing a subsequent mass spectrometry analysis to determine the molecular weight of said chemically altered analyte molecules.
5. The method according to claim 2 wherein said affinity reagent is chemically bonded to said face of said probe tip.
6. The method according to claim 2 wherein said affinity reagent is physically adhered to said face of said probe tip.
7. The method according to claim 2 wherein said affinity reagent is adapted to chemically bond to said analyte molecules.
8. The method according to claim 2 wherein said affinity reagent is adapted to biologically adhere to said analyte molecules.
9. The method according to claim 2 wherein said analyte molecules are biomolecules and said affinity reagent is adapted to selectively isolate said biomolecules from an undifferentiated biological sample.
10. The method according to claim 3 wherein said matrix materials are in the weakly acidic to strongly basic pH range.
11. The method according to claim 3 wherein said matrix materials have a pH above 6.0.
12. The method according to claim 2 wherein said face of said probe tip is formed of an electrically insulating material.
13. A method of measuring the mass of analyte molecules by means of laser desorption/ionization, time-of-flight mass spectrometry in which a matrix material is used in conjunction with said analyte molecules for facilitating desorption and ionization of the analyte molecules, the improvement comprising:
presenting the analyte molecules on or above the surface of the matrix material, whereby at least a portion of the analyte molecules not desorbed in said mass spectrometry analysis remain chemically accessible for subsequent analytical procedures, in situ, on said probe tip, without the necessity for separating said portion of said analyte molecules from said matrix material.
14. An apparatus for facilitating desorption and ionization of analyte molecules for analysis by mass spectrometry, said apparatus comprising:
a substrate; and
an affinity reagent attached to said substrate and having means for selectively bonding with said analyte molecules.
15. The apparatus according to claim 14 wherein said substrate comprises the surface of a probe tip for use in a time-of-flight mass spectrometry analyzer.
16. The apparatus according to claim 14 wherein said affinity reagent is chemically bonded to said substrate.
17. The apparatus according to claim 14 wherein said affinity reagent is physically adhered to said substrate.
18. The apparatus according to claim 14 wherein said affinity reagent is adapted to chemically bond to said analyte molecules.
19. The apparatus according to claim 14 wherein said affinity reagent is adapted to biologically adhere to said analyte molecules.
20. The apparatus according to claim 14 wherein said analyte molecules are biomolecules and said affinity reagent is adapted to selectively isolate said biomolecules from an undifferentiated biological sample.
21. The apparatus according to claim 14 comprising additionally a matrix material deposited on said substrate in association with said affinity reagent in a manner so as to not render ineffective said means on said affinity reagents for selective bonding with said analyte molecules.
22. The apparatus according to claim 21 wherein said matrix material is in the weakly acidic to strongly basic pH range.
23. The apparatus according to claim 21 wherein said matrix material has a pH above 6.0.
24. The apparatus according to claim 14 wherein said substrate is formed of an electrically insulating material.
25. A method for preparing a surface for presenting analyte molecules for analysis by time-of-flight mass spectrometry, said method comprising:
providing a substrate on said surface for supporting said analyte;
derivitizing said substrate with an affinity reagent having means for selectively bonding with said analyte; and
depositing a desorption/ionization promoting matrix material on said substrate in association with said affinity reagent, said matrix material being deposited in a manner so as to not render ineffective said means on said affinity reagent for selectively bonding with said analyte.
26. A method for preparing a surface for presenting analyte molecules for analysis, said method comprising:
providing a substrate on said surface for supporting said analyte;
derivitizing said substrate with an affinity reagent having means for selectively bonding with said analyte; and
a means for detection of said analyte molecules bonded with said affinity reagent.
27. The method according to claim 26 comprising additionally the step of applying a detection material to said surface.
28. The method according to claim 27 wherein such detection material comprises a fluorescing species.
29. The method according to claim 27 wherein such detection material comprises an enzymatic species.
30. The method according to claim 27 comprising additionally wherein such detection material comprises a radioactive species.
31. The method according to claim 27 comprising additionally wherein such detection material comprises a light-emitting species.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/728,442 US20040191922A1 (en) | 1993-05-28 | 2003-12-05 | Method and apparatus for desorption and ionization of analytes |
US11/347,495 US7449150B2 (en) | 1993-05-28 | 2006-02-03 | Probe and apparatus for desorption and ionization of analytes |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6889693A | 1993-05-28 | 1993-05-28 | |
US09/809,657 US6734022B2 (en) | 1993-05-28 | 2001-03-15 | Method and apparatus for desorption and ionization of analytes |
US10/728,442 US20040191922A1 (en) | 1993-05-28 | 2003-12-05 | Method and apparatus for desorption and ionization of analytes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/809,657 Continuation US6734022B2 (en) | 1993-05-28 | 2001-03-15 | Method and apparatus for desorption and ionization of analytes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/347,495 Continuation US7449150B2 (en) | 1993-05-28 | 2006-02-03 | Probe and apparatus for desorption and ionization of analytes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040191922A1 true US20040191922A1 (en) | 2004-09-30 |
Family
ID=22085400
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/483,357 Expired - Lifetime US5719060A (en) | 1993-05-28 | 1995-06-07 | Method and apparatus for desorption and ionization of analytes |
US08/785,636 Expired - Lifetime US6027942A (en) | 1993-05-28 | 1997-01-17 | Surface-enhanced affinity capture for desorption and detection or analytes |
US08/785,637 Expired - Fee Related US5894063A (en) | 1993-05-28 | 1997-01-17 | Surface-enhanced neat desorption for disorption and detection of analytes |
US09/095,407 Expired - Lifetime US6124137A (en) | 1993-05-28 | 1998-06-10 | Surface-enhanced photolabile attachment and release for desorption and detection of analytes |
US09/123,253 Expired - Fee Related US7071003B2 (en) | 1993-05-28 | 1998-07-27 | Surface-enhanced laser desorption/Ionization for desorption and detection of analytes |
US09/742,494 Expired - Lifetime US6528320B2 (en) | 1993-05-28 | 2000-12-20 | Method and apparatus for desorption and ionization of analytes |
US09/809,657 Expired - Fee Related US6734022B2 (en) | 1993-05-28 | 2001-03-15 | Method and apparatus for desorption and ionization of analytes |
US10/728,442 Abandoned US20040191922A1 (en) | 1993-05-28 | 2003-12-05 | Method and apparatus for desorption and ionization of analytes |
US11/347,495 Expired - Fee Related US7449150B2 (en) | 1993-05-28 | 2006-02-03 | Probe and apparatus for desorption and ionization of analytes |
Family Applications Before (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/483,357 Expired - Lifetime US5719060A (en) | 1993-05-28 | 1995-06-07 | Method and apparatus for desorption and ionization of analytes |
US08/785,636 Expired - Lifetime US6027942A (en) | 1993-05-28 | 1997-01-17 | Surface-enhanced affinity capture for desorption and detection or analytes |
US08/785,637 Expired - Fee Related US5894063A (en) | 1993-05-28 | 1997-01-17 | Surface-enhanced neat desorption for disorption and detection of analytes |
US09/095,407 Expired - Lifetime US6124137A (en) | 1993-05-28 | 1998-06-10 | Surface-enhanced photolabile attachment and release for desorption and detection of analytes |
US09/123,253 Expired - Fee Related US7071003B2 (en) | 1993-05-28 | 1998-07-27 | Surface-enhanced laser desorption/Ionization for desorption and detection of analytes |
US09/742,494 Expired - Lifetime US6528320B2 (en) | 1993-05-28 | 2000-12-20 | Method and apparatus for desorption and ionization of analytes |
US09/809,657 Expired - Fee Related US6734022B2 (en) | 1993-05-28 | 2001-03-15 | Method and apparatus for desorption and ionization of analytes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/347,495 Expired - Fee Related US7449150B2 (en) | 1993-05-28 | 2006-02-03 | Probe and apparatus for desorption and ionization of analytes |
Country Status (12)
Country | Link |
---|---|
US (9) | US5719060A (en) |
EP (2) | EP1347493A3 (en) |
JP (3) | JP3639594B2 (en) |
AT (1) | ATE242485T1 (en) |
AU (1) | AU676582B2 (en) |
CA (2) | CA2512290C (en) |
DE (1) | DE69432791T2 (en) |
DK (1) | DK0700521T3 (en) |
ES (1) | ES2201077T3 (en) |
NZ (1) | NZ267842A (en) |
PT (1) | PT700521E (en) |
WO (1) | WO1994028418A1 (en) |
Families Citing this family (421)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0664884A4 (en) * | 1992-05-29 | 1997-05-02 | Univ Rockefeller | Method and product for the sequence determination of peptides using a mass spectrometer. |
US6436635B1 (en) * | 1992-11-06 | 2002-08-20 | Boston University | Solid phase sequencing of double-stranded nucleic acids |
US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
US20020037517A1 (en) * | 1993-05-28 | 2002-03-28 | Hutchens T. William | Methods for sequencing biopolymers |
CA2512290C (en) * | 1993-05-28 | 2010-02-02 | Baylor College Of Medicine | Method and apparatus for desorption and ionization of analytes |
US6071610A (en) * | 1993-11-12 | 2000-06-06 | Waters Investments Limited | Enhanced resolution matrix-laser desorption and ionization TOF-MS sample surface |
US7803529B1 (en) | 1995-04-11 | 2010-09-28 | Sequenom, Inc. | Solid phase sequencing of biopolymers |
US20060063193A1 (en) * | 1995-04-11 | 2006-03-23 | Dong-Jing Fu | Solid phase sequencing of double-stranded nucleic acids |
US20020164818A1 (en) * | 1995-05-23 | 2002-11-07 | Gruber Karl F. | Mass spectrometric immunoassay analysis of specific proteins and variants present in various biological fluids |
US20030027216A1 (en) * | 2001-07-02 | 2003-02-06 | Kiernan Urban A. | Analysis of proteins from biological fluids using mass spectrometric immunoassay |
WO1996037777A1 (en) | 1995-05-23 | 1996-11-28 | Nelson Randall W | Mass spectrometric immunoassay |
US6004770A (en) * | 1995-06-07 | 1999-12-21 | Arizona State University Board Of Regents | Sample presentation apparatus for mass spectrometry |
CA2221250C (en) * | 1995-06-07 | 2007-11-20 | Arizona Board Of Regents | A sample presentation apparatus for mass spectrometry |
AU756020B2 (en) * | 1995-06-07 | 2003-01-02 | Arizona Board Of Regents, The | A sample presentation apparatus for mass spectrometry |
US6316266B1 (en) | 1995-06-07 | 2001-11-13 | Arizona State University Board Of Regents | Sample presentation apparatus for mass spectrometry |
US6093541A (en) * | 1995-06-07 | 2000-07-25 | Arizona State University Board Of Regents | Mass spectrometer having a derivatized sample presentation apparatus |
GB9518429D0 (en) * | 1995-09-08 | 1995-11-08 | Pharmacia Biosensor | A rapid method for providing kinetic and structural data in molecular interaction analysis |
WO1997012989A1 (en) | 1995-10-02 | 1997-04-10 | Katoot Mohammad W | Biologically-active polymers |
US5716825A (en) * | 1995-11-01 | 1998-02-10 | Hewlett Packard Company | Integrated nucleic acid analysis system for MALDI-TOF MS |
US5705813A (en) * | 1995-11-01 | 1998-01-06 | Hewlett-Packard Company | Integrated planar liquid handling system for maldi-TOF MS |
US6312893B1 (en) | 1996-01-23 | 2001-11-06 | Qiagen Genomics, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
US6027890A (en) * | 1996-01-23 | 2000-02-22 | Rapigene, Inc. | Methods and compositions for enhancing sensitivity in the analysis of biological-based assays |
US6613508B1 (en) | 1996-01-23 | 2003-09-02 | Qiagen Genomics, Inc. | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques |
SE9602545L (en) * | 1996-06-25 | 1997-12-26 | Michael Mecklenburg | Method of discriminating complex biological samples |
US7285422B1 (en) * | 1997-01-23 | 2007-10-23 | Sequenom, Inc. | Systems and methods for preparing and analyzing low volume analyte array elements |
US6818394B1 (en) | 1996-11-06 | 2004-11-16 | Sequenom, Inc. | High density immobilization of nucleic acids |
US6024925A (en) | 1997-01-23 | 2000-02-15 | Sequenom, Inc. | Systems and methods for preparing low volume analyte array elements |
EP0881494A1 (en) * | 1997-04-29 | 1998-12-02 | Roche Diagnostics GmbH | Method of simultaneous determination of proteins and their derivatives |
US6451616B1 (en) | 1997-05-19 | 2002-09-17 | Robert W. Odom | Analysis of molecules bound to solid surfaces using selective bond cleavage processes |
AU2002301047B2 (en) * | 1997-06-20 | 2005-11-10 | Ciphergen Biosystems, Inc. | Retentate Chromatography And Protein Chip Arrays With Applications In Biology And Medicine |
EP1387390B1 (en) | 1997-06-20 | 2009-02-18 | Bio - Rad Laboratories, Inc. | Retentate chromatography and protein chip arrays with applications in biology and medicine |
AU2003235062B2 (en) * | 1997-06-20 | 2006-02-02 | Ciphergen Biosystems, Inc. | Retentate chromatography and protein chip arrays with applications in biology and medicine |
NZ516848A (en) * | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
US6207370B1 (en) | 1997-09-02 | 2001-03-27 | Sequenom, Inc. | Diagnostics based on mass spectrometric detection of translated target polypeptides |
US5952654A (en) * | 1997-10-29 | 1999-09-14 | Northeastern University | Field-release mass spectrometry |
DE69938623T2 (en) | 1998-02-04 | 2009-05-28 | Invitrogen Corp., Carlsbad | MICROARRAYS AND ITS USES |
US6849847B1 (en) | 1998-06-12 | 2005-02-01 | Agilent Technologies, Inc. | Ambient pressure matrix-assisted laser desorption ionization (MALDI) apparatus and method of analysis |
US6221626B1 (en) | 1998-06-30 | 2001-04-24 | University Of Geneva | Kit for electroblotting polypeptides separated on an electrophoresis gel |
US20020119579A1 (en) * | 1998-07-14 | 2002-08-29 | Peter Wagner | Arrays devices and methods of use thereof |
US6780582B1 (en) * | 1998-07-14 | 2004-08-24 | Zyomyx, Inc. | Arrays of protein-capture agents and methods of use thereof |
US6576478B1 (en) * | 1998-07-14 | 2003-06-10 | Zyomyx, Inc. | Microdevices for high-throughput screening of biomolecules |
US6682942B1 (en) | 1998-07-14 | 2004-01-27 | Zyomyx, Inc. | Microdevices for screening biomolecules |
US6897073B2 (en) * | 1998-07-14 | 2005-05-24 | Zyomyx, Inc. | Non-specific binding resistant protein arrays and methods for making the same |
US6406921B1 (en) * | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
US6206840B1 (en) * | 1998-08-12 | 2001-03-27 | Siemens Aktiengesellschaft | Method for the identification of a liquid secreted by a living subject particularly for identification of amniotic fluid |
GB9821393D0 (en) * | 1998-10-01 | 1998-11-25 | Brax Genomics Ltd | Protein profiling 2 |
US20060172925A1 (en) * | 1998-10-26 | 2006-08-03 | Board Of Regents, The University Of Texas System | Thio-siRNA aptamers |
US20040242521A1 (en) * | 1999-10-25 | 2004-12-02 | Board Of Regents, The University Of Texas System | Thio-siRNA aptamers |
US6423493B1 (en) * | 1998-10-26 | 2002-07-23 | Board Of Regents The University Of Texas System | Combinatorial selection of oligonucleotide aptamers |
AU766334B2 (en) * | 1999-01-28 | 2003-10-16 | Universite De Geneve | Method and kit for identifying or characterising polypeptides |
ATE469699T1 (en) * | 1999-02-23 | 2010-06-15 | Caliper Life Sciences Inc | MANIPULATION OF MICROPARTICLES IN MICROFLUID SYSTEMS |
EP1166329A4 (en) * | 1999-03-09 | 2005-03-23 | Scripps Research Inst | Improved desorption/ionization of analytes from porous light-absorbing semiconductor |
CN1204592C (en) | 1999-04-27 | 2005-06-01 | 赛弗根生物系统股份有限公司 | Probes for gas phase ion spectrometer |
CN1169188C (en) | 1999-04-29 | 2004-09-29 | 赛弗根生物系统股份有限公司 | Sample holder with hydrophobic coating for gas phase mass spectrometers |
ATE421976T1 (en) | 1999-05-18 | 2009-02-15 | Dyax Corp | FAB FRAGMENT LIBRARIES AND METHODS FOR USE THEREOF |
WO2000077812A2 (en) * | 1999-06-10 | 2000-12-21 | Northeastern University | Light-induced electron capture at a surface |
US20090233806A1 (en) * | 1999-07-06 | 2009-09-17 | Carr Francis J | Protein isolation and analysis |
US7138254B2 (en) | 1999-08-02 | 2006-11-21 | Ge Healthcare (Sv) Corp. | Methods and apparatus for performing submicroliter reactions with nucleic acids or proteins |
AU7331500A (en) | 1999-08-27 | 2001-03-26 | Large Scale Proteomics, Corp. | Devices for use in maldi mass spectrometry |
US6869572B1 (en) * | 1999-09-13 | 2005-03-22 | Millipore Corporation | High density cast-in-place sample preparation card |
JP4014767B2 (en) * | 1999-09-17 | 2007-11-28 | 富士フイルム株式会社 | Rigid macro array |
US7167615B1 (en) | 1999-11-05 | 2007-01-23 | Board Of Regents, The University Of Texas System | Resonant waveguide-grating filters and sensors and methods for making and using same |
US6936424B1 (en) | 1999-11-16 | 2005-08-30 | Matritech, Inc. | Materials and methods for detection and treatment of breast cancer |
CA2394942A1 (en) * | 1999-12-20 | 2001-06-28 | Stephen J. Fonash | Deposited thin films and their use in detection, attachment, and bio-medical applications |
US20030087265A1 (en) * | 2000-01-21 | 2003-05-08 | Edward Sauter | Specific microarrays for breast cancer screening |
WO2001062887A1 (en) | 2000-02-23 | 2001-08-30 | Zyomyx, Inc. | Chips having elevated sample surfaces |
US7351540B1 (en) * | 2000-03-17 | 2008-04-01 | Merck Patent Gmbh | Protein isolation and analysis |
CA2301451A1 (en) * | 2000-03-20 | 2001-09-21 | Thang T. Pham | Method for analysis of analytes by mass spectrometry |
US7122790B2 (en) * | 2000-05-30 | 2006-10-17 | The Penn State Research Foundation | Matrix-free desorption ionization mass spectrometry using tailored morphology layer devices |
NZ522859A (en) * | 2000-06-19 | 2005-08-26 | Correlogic Systems Inc | Heuristic method of classifying objects using a vector space having multiple preclassified data clusters |
WO2002004628A2 (en) * | 2000-07-06 | 2002-01-17 | Genvec, Inc. | Method of identifying a binding partner of a gene product |
IL153856A0 (en) * | 2000-07-18 | 2003-07-31 | Correlogic Systems Inc | A process for discriminating between biological states based on hidden patterns from biological data |
ATE282205T1 (en) | 2000-07-24 | 2004-11-15 | Health Research Inc | METHOD FOR DETECTING PROSTATE-SPECIFIC MEMBRANE ANTIGEN IN SERUM |
DE10043042C2 (en) * | 2000-09-01 | 2003-04-17 | Bruker Daltonik Gmbh | Method for loading a sample carrier with biomolecules for mass spectrometric analysis |
JP4706093B2 (en) * | 2000-09-25 | 2011-06-22 | 富士レビオ株式会社 | Method for removing and purifying parvovirus |
CA2425434A1 (en) * | 2000-10-11 | 2002-04-18 | Tina Morris | Methods for characterizing molecular interactions using affinity capture tandem mass spectrometry |
US20020142483A1 (en) | 2000-10-30 | 2002-10-03 | Sequenom, Inc. | Method and apparatus for delivery of submicroliter volumes onto a substrate |
US7407773B2 (en) * | 2000-11-03 | 2008-08-05 | Procognia, Ltd. | Method for characterizing a carbohydrate polymer |
US6864065B2 (en) * | 2000-11-08 | 2005-03-08 | Surface Logix, Inc. | Assays for monitoring cell motility in real-time |
US7326563B2 (en) | 2000-11-08 | 2008-02-05 | Surface Logix, Inc. | Device and method for monitoring leukocyte migration |
US7033819B2 (en) | 2000-11-08 | 2006-04-25 | Surface Logix, Inc. | System for monitoring cell motility in real-time |
US7374906B2 (en) | 2000-11-08 | 2008-05-20 | Surface Logix, Inc. | Biological assays using gradients formed in microfluidic systems |
US6893851B2 (en) | 2000-11-08 | 2005-05-17 | Surface Logix, Inc. | Method for arraying biomolecules and for monitoring cell motility in real-time |
US6699665B1 (en) * | 2000-11-08 | 2004-03-02 | Surface Logix, Inc. | Multiple array system for integrating bioarrays |
US6844184B2 (en) * | 2000-11-08 | 2005-01-18 | Surface Logix, Inc. | Device for arraying biomolecules and for monitoring cell motility in real-time |
US7033821B2 (en) * | 2000-11-08 | 2006-04-25 | Surface Logix, Inc. | Device for monitoring cell motility in real-time |
US20030129666A1 (en) * | 2001-01-09 | 2003-07-10 | Mitsubishi Pharma Corporation | Novel proteome analysis method and devices therefor |
JP2002228668A (en) * | 2001-01-31 | 2002-08-14 | Shimadzu Corp | Automatic sampler |
CA2436503A1 (en) * | 2001-02-01 | 2002-08-08 | Huw A. Davies | Improved methods for protein identification, characterization and sequencing by tandem mass spectrometry |
WO2002064621A2 (en) * | 2001-02-14 | 2002-08-22 | Attenuon, Llc | Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent |
WO2002071066A1 (en) * | 2001-03-02 | 2002-09-12 | Activx Biosciences, Inc. | Protein profiling platform |
US20030228639A1 (en) * | 2001-03-19 | 2003-12-11 | Wright George L | Prostate cancer markers |
US20030219734A1 (en) * | 2001-04-13 | 2003-11-27 | Biosite Incorporated | Polypeptides related to natriuretic peptides and methods of their identification and use |
US7524635B2 (en) * | 2003-04-17 | 2009-04-28 | Biosite Incorporated | Methods and compositions for measuring natriuretic peptides and uses thereof |
US6804410B2 (en) | 2001-04-17 | 2004-10-12 | Large Scale Proteomics Corporation | System for optimizing alignment of laser beam with selected points on samples in MALDI mass spectrometer |
EP1385998A1 (en) * | 2001-04-19 | 2004-02-04 | Ciphergen Biosystems, Inc. | Biomolecule characterization using mass spectrometry and affinity tags |
US20020155587A1 (en) | 2001-04-20 | 2002-10-24 | Sequenom, Inc. | System and method for testing a biological sample |
WO2002093170A1 (en) * | 2001-05-14 | 2002-11-21 | The Penn State Research Foundation | Matrix-free desorption ionization mass spectrometry using tailored morphology layer devices |
US6825032B2 (en) * | 2001-05-14 | 2004-11-30 | Sigma-Aldrich Co. | High capacity assay platforms |
AU2002305710A1 (en) * | 2001-05-25 | 2002-12-09 | Waters Investments Limited | Sample concentration maldi plates for maldi mass spectrometry |
WO2002096541A1 (en) * | 2001-05-25 | 2002-12-05 | Waters Investments Limited | Desalting plate for maldi mass spectrometry |
JP4264002B2 (en) * | 2001-07-17 | 2009-05-13 | バイオ−ラド ラボラトリーズ インコーポレイテッド | Latex-based adsorption chip |
GB0120131D0 (en) * | 2001-08-17 | 2001-10-10 | Micromass Ltd | Maldi target plate |
EP1421189A2 (en) * | 2001-08-22 | 2004-05-26 | Helix Biopharma Corp. | Method and device for integrated protein expression, purification and detection |
WO2003019193A1 (en) * | 2001-08-30 | 2003-03-06 | Ciphergen Biosystems, Inc. | Method of diagnosing nephrotic syndrome |
US20040043436A1 (en) * | 2001-09-21 | 2004-03-04 | Antonia Vlahou | Biomarkers of transitional cell carcinoma of the bladder |
US7842498B2 (en) | 2001-11-08 | 2010-11-30 | Bio-Rad Laboratories, Inc. | Hydrophobic surface chip |
US20030091976A1 (en) * | 2001-11-14 | 2003-05-15 | Ciphergen Biosystems, Inc. | Methods for monitoring polypeptide production and purification using surface enhanced laser desorption/ionization mass spectrometry |
US20030162190A1 (en) * | 2001-11-15 | 2003-08-28 | Gorenstein David G. | Phosphoromonothioate and phosphorodithioate oligonucleotide aptamer chip for functional proteomics |
US20040018519A1 (en) * | 2001-11-16 | 2004-01-29 | Wright ,Jr. George L | Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers |
US6946653B2 (en) | 2001-11-27 | 2005-09-20 | Ciphergen Biosystems, Inc. | Methods and apparatus for improved laser desorption ionization tandem mass spectrometry |
GB2384778A (en) * | 2001-12-21 | 2003-08-06 | Sense Proteomic Ltd | Probe for mass spectrometry |
US20030207462A1 (en) * | 2002-01-25 | 2003-11-06 | Ciphergen Biosystems, Inc. | Monomers and polymers having energy absorbing moieties of use in desorption/ionization of analytes |
EP1481244A4 (en) * | 2002-01-25 | 2008-07-02 | Bio Rad Laboratories | Monomers and polymers having energy absorbing moieties of use in desorption/ionization of analytes |
WO2003072710A2 (en) * | 2002-02-21 | 2003-09-04 | Eastern Virginia Medical School | Protein biomarkers that distinguish prostate cancer from non-malignant cells |
US20030232396A1 (en) * | 2002-02-22 | 2003-12-18 | Biolife Solutions, Inc. | Method and use of protein microarray technology and proteomic analysis to determine efficacy of human and xenographic cell, tissue and organ transplant |
US20090149335A1 (en) * | 2002-02-22 | 2009-06-11 | Biolife Solutions Inc. | Method and use of microarray technology and proteogenomic analysis to predict efficacy of human and xenographic cell, tissue and organ transplant |
WO2003074571A2 (en) * | 2002-02-28 | 2003-09-12 | Keck Graduate Institute | Cationic polyelectrolytes in biomolecule purification and analysis |
US9870907B2 (en) * | 2002-03-11 | 2018-01-16 | Jp Scientific Limited | Probe for extraction of molecules of interest from a sample |
US20090026122A1 (en) | 2002-03-11 | 2009-01-29 | Janusz | Biocompatible solid-phase microextraction coatings and methods for their preparation |
US9733234B2 (en) | 2002-03-11 | 2017-08-15 | Jp Scientific Limited | Probe for extraction of molecules of interest from a sample |
US20060084059A1 (en) * | 2002-04-08 | 2006-04-20 | Tai-Tung Yip | Serum biomarkers in hepatocellular carcinoma |
AUPS177202A0 (en) * | 2002-04-16 | 2002-05-23 | Diakyne Pty Ltd | Multi-element screening of trace elements |
AU2003265769A1 (en) * | 2002-05-02 | 2003-11-17 | Ciphergen Biosystems, Inc. | Biochips with surfaces coated with polysaccharide based hydrogels |
WO2004030511A2 (en) * | 2002-05-10 | 2004-04-15 | Eastern Virginia Medical School | Prostate cancer biomarkers |
US20040033613A1 (en) * | 2002-05-30 | 2004-02-19 | Zwick Michael G. | Saliva-based protein profiling |
WO2003101394A2 (en) * | 2002-05-31 | 2003-12-11 | Ciphergen Biosystems, Inc. | Defensins: use as antiviral agents |
US7109038B2 (en) * | 2002-06-13 | 2006-09-19 | The Johns Hopkins University | Occult blood detection in biological samples by laser desorption and matrix-assisted laser desorption/ionization mass spectrometry for biomedical applications |
WO2004009798A2 (en) * | 2002-07-24 | 2004-01-29 | Ciphergen Biosystems, Inc. | Protein interaction difference mapping |
AR040712A1 (en) | 2002-07-29 | 2005-04-20 | Correlogic Systems Inc | A METHOD FOR INITIATING A CONTROL MODEL FOR THE BIO TEST PROCESS |
US6624409B1 (en) | 2002-07-30 | 2003-09-23 | Agilent Technologies, Inc. | Matrix assisted laser desorption substrates for biological and reactive samples |
WO2004013290A2 (en) * | 2002-08-05 | 2004-02-12 | Invitrogen Corporation | Compositions and methods for molecular biology |
JP4644123B2 (en) * | 2002-08-06 | 2011-03-02 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Use of biomarkers to detect ovarian cancer |
AU2003304434A1 (en) * | 2002-08-06 | 2005-03-07 | The Johns Hopkins University | System, software and methods for biomarker identification |
US20050233473A1 (en) * | 2002-08-16 | 2005-10-20 | Zyomyx, Inc. | Methods and reagents for surface functionalization |
WO2004016586A2 (en) * | 2002-08-16 | 2004-02-26 | Board Of Regents The University Of Texas System | Compositions and methods related to flavivirus envelope protein domain iii antigens |
US20030119063A1 (en) * | 2002-09-03 | 2003-06-26 | Pham Thang T. | High accuracy protein identification |
US20040050787A1 (en) * | 2002-09-13 | 2004-03-18 | Elena Chernokalskaya | Apparatus and method for sample preparation and direct spotting eluants onto a MALDI-TOF target |
WO2004024318A1 (en) * | 2002-09-13 | 2004-03-25 | Pall Corporation | Preparation and use of mixed mode solid substrates for chromatography adsorbents and biochip arrays |
US20060292701A1 (en) * | 2002-09-13 | 2006-12-28 | Ciphergen Biosystems Inc. | Photocrosslinked hydrogel blend surface coatings |
US7045366B2 (en) * | 2003-09-12 | 2006-05-16 | Ciphergen Biosystems, Inc. | Photocrosslinked hydrogel blend surface coatings |
KR20050070034A (en) | 2002-10-04 | 2005-07-05 | 미쯔비시 웰 파마 가부시키가이샤 | Plate for mass spectrometry, process for preparing the same and use thereof |
EP1572978A4 (en) * | 2002-10-16 | 2006-05-24 | Univ Texas | Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries |
US7122384B2 (en) * | 2002-11-06 | 2006-10-17 | E. I. Du Pont De Nemours And Company | Resonant light scattering microparticle methods |
AU2003291483A1 (en) | 2002-11-12 | 2004-06-03 | Becton, Dickinson And Company | Diagnosis of sepsis or sirs using biomarker profiles |
MXPA05005071A (en) | 2002-11-12 | 2005-07-22 | Becton Dickinson Co | Diagnosis of sepsis or sirs using biomarker profiles. |
JP2006511790A (en) * | 2002-11-14 | 2006-04-06 | サイファージェン バイオシステムズ インコーポレイテッド | Biomarkers for intra-amniotic inflammation |
US7105809B2 (en) * | 2002-11-18 | 2006-09-12 | 3M Innovative Properties Company | Microstructured polymeric substrate |
US7846748B2 (en) * | 2002-12-02 | 2010-12-07 | The University Of North Carolina At Chapel Hill | Methods of quantitation and identification of peptides and proteins |
EP1739185A1 (en) | 2002-12-18 | 2007-01-03 | Ciphergen Biosystems, Inc. | Serum biomarkers in lung cancer |
JP2006512076A (en) * | 2002-12-31 | 2006-04-13 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | Canine L-PBE sequence |
WO2004057940A2 (en) * | 2002-12-31 | 2004-07-15 | Pharmacia & Upjohn Company Llc | Canine dioxin/aryl hydrocarbon receptor sequences |
JP2006512075A (en) * | 2002-12-31 | 2006-04-13 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | Canine CYP1A2 sequence |
US20170212128A1 (en) | 2004-01-13 | 2017-07-27 | Tianxin Wang | Methods and compositions for mass spectrometry analysis |
US8119416B2 (en) * | 2004-01-13 | 2012-02-21 | Wuxi WeiYi Zhinengkeji, Inc. | MALDI analysis using modified matrices with affinity groups for non-covalent binding with analytes |
DE112004000250T5 (en) * | 2003-02-10 | 2006-02-16 | Waters Investments Ltd., New Castle | Sample preparation plate for mass spectrometry |
WO2005029003A2 (en) * | 2003-02-10 | 2005-03-31 | Waters Investments Limited | Identification of air components with silicon mass spectrometry |
US20060141470A1 (en) * | 2003-02-14 | 2006-06-29 | Kalayoglu Murat V | Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof |
DE10311384A1 (en) * | 2003-03-11 | 2004-09-30 | Universität Potsdam | Detection method for plant molecules |
US20040185448A1 (en) * | 2003-03-20 | 2004-09-23 | Viorica Lopez-Avila | Methods and devices for performing matrix assisted laser desorption/lonization protocols |
US6977370B1 (en) * | 2003-04-07 | 2005-12-20 | Ciphergen Biosystems, Inc. | Off-resonance mid-IR laser desorption ionization |
US20050233390A1 (en) * | 2003-04-09 | 2005-10-20 | Allen John W | Device including a proteinaceous factor, a recombinant proteinaceous factor, and a nucleotide sequence encoding the proteinaceous factor |
WO2004094460A2 (en) | 2003-04-17 | 2004-11-04 | Ciphergen Biosystems, Inc. | Polypeptides related to natriuretic peptides and methods of their identification and use |
EP1616180A4 (en) * | 2003-04-22 | 2006-07-19 | Ciphergen Biosystems Inc | Methods of host cell protein analysis |
US20060177870A1 (en) * | 2003-04-28 | 2006-08-10 | Ciphergen Biosystems, Inc | Immunoassays |
US7138625B2 (en) * | 2003-05-02 | 2006-11-21 | Agilent Technologies, Inc. | User customizable plate handling for MALDI mass spectrometry |
WO2004103155A2 (en) * | 2003-05-16 | 2004-12-02 | Ciphergen Biosystems, Inc. | Surface-enhanced laser desorption/ionization-based disease diagnosis |
CA2526691A1 (en) * | 2003-05-23 | 2005-04-28 | Board Of Regents - The University Of Texas System | High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens |
US7910523B2 (en) * | 2003-05-23 | 2011-03-22 | Board Of Regents, The University Of Texas System | Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors |
WO2004111654A2 (en) * | 2003-06-06 | 2004-12-23 | Ciphergen Biosystems, Inc. | Serum biomarkers in ischaemic heart disease |
US20050023456A1 (en) * | 2003-06-09 | 2005-02-03 | The Regents Of The University Of California | Matrix for MALDI analysis based on porous polymer monoliths |
WO2005008247A2 (en) * | 2003-07-11 | 2005-01-27 | Science & Technology Corporation @ Unm. | Detection of endometrial pathology |
US20050032113A1 (en) * | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
US20050118611A1 (en) * | 2003-07-24 | 2005-06-02 | Board Of Regents, The University Of Texas System | Thioaptamers enable discovery of physiological pathways and new therapeutic strategies |
SG145705A1 (en) * | 2003-08-01 | 2008-09-29 | Correlogic Systems Inc | Multiple high-resolution serum proteomic features for ovarian cancer detection |
US6977143B1 (en) * | 2003-09-08 | 2005-12-20 | Quest Diagnostics Investments Incorporated | Determination of testosterone by mass spectrometry |
US20050079631A1 (en) * | 2003-10-09 | 2005-04-14 | Science & Engineering Services, Inc. | Method and apparatus for ionization of a sample at atmospheric pressure using a laser |
US20050112650A1 (en) * | 2003-10-20 | 2005-05-26 | Ciphergen Biosystems, Inc. | Reactive polyurethane-based polymers |
AU2004286240A1 (en) * | 2003-10-23 | 2005-05-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Biomarkers for amyotrophic lateral sclerosis |
EP2369348A1 (en) | 2003-11-07 | 2011-09-28 | Ciphergen Biosystems, Inc. | Biomarkers for Alzheimer's disease |
US8043825B2 (en) * | 2003-12-05 | 2011-10-25 | Mcgill University | Serum biomarkers for Chagas disease |
US20050186645A1 (en) * | 2003-12-18 | 2005-08-25 | Yehudit Amor | Method for analyzing a glycomolecule |
WO2005061532A1 (en) * | 2003-12-23 | 2005-07-07 | Berthet Francois Xavier | Pathogenic infection detection compositions and methods |
US7183544B2 (en) * | 2003-12-31 | 2007-02-27 | Ciphergen Biosystems Inc. | Bi-functional polymer chip |
US20050181398A1 (en) * | 2004-01-16 | 2005-08-18 | Fung Eric T. | Specific detection of host response protein clusters |
US8021889B2 (en) * | 2004-01-20 | 2011-09-20 | Pall Corporation | Chromatographic material for the absorption of proteins at physiological ionic strength |
US20050181513A1 (en) * | 2004-02-18 | 2005-08-18 | Viorica Lopez-Avila | Methods and compositions for assessing a sample by MAILDI mass spectrometry |
US20050233400A1 (en) * | 2004-03-03 | 2005-10-20 | Weiner Carl P | Proteomic method for predicting success of rescue cerclage |
EP1580559B1 (en) | 2004-03-23 | 2013-12-25 | Bio-Rad Laboratories, Inc. | Methods for reducing the variance between analyte concentrations taken from complex sample mixtures |
US20060275923A1 (en) * | 2004-03-23 | 2006-12-07 | Hammond David J | Methods for reducing the range in concentrations of analyte species in a sample |
CA2578670C (en) | 2004-04-15 | 2017-03-07 | University Of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
US20050239134A1 (en) * | 2004-04-21 | 2005-10-27 | Board Of Regents, The University Of Texas System | Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein |
EP2520310B1 (en) * | 2004-04-23 | 2016-03-30 | Zoetis Services LLC | Cellular permissivity factor for viruses, and uses thereof |
WO2005103281A2 (en) | 2004-04-26 | 2005-11-03 | Children's Medical Center Corporation | Platelet biomarkers for the detection of disease |
US20060023808A1 (en) * | 2004-05-17 | 2006-02-02 | Hajivandi Mahbod R | Compositions, kits, and methods for calibration in mass spectrometry |
US20090215192A1 (en) * | 2004-05-27 | 2009-08-27 | Stratos Biosystems, Llc | Solid-phase affinity-based method for preparing and manipulating an analyte-containing solution |
ATE534750T1 (en) | 2004-07-30 | 2011-12-15 | Adeza Biomedical Corp | ONCOFETAL FIBRONECTIN AS A CERVICAL CARCINOMA MARKER |
US7786261B2 (en) * | 2004-09-02 | 2010-08-31 | National Research Council Of Canada | Coiled-coil fusion proteins comprising cell receptor domains |
CA2480549A1 (en) | 2004-09-15 | 2006-03-15 | Phytronix Technologies Inc. | Ionization source for mass spectrometer |
US7391018B2 (en) * | 2004-09-17 | 2008-06-24 | Nanosys, Inc. | Nanostructured thin films and their uses |
WO2006034278A2 (en) * | 2004-09-21 | 2006-03-30 | Matritech, Inc. | Methods and compositions for detecting cancer using components of the u2 spliceosomal particle |
EP1802961A4 (en) * | 2004-09-29 | 2007-11-14 | Bio Rad Laboratories | Host-guest enery-absorbing complex |
WO2006047417A2 (en) | 2004-10-21 | 2006-05-04 | University Of Florida Research Foundation, Inc. | Detection of cannabinoid receptor biomarkers and uses thereof |
JP4636859B2 (en) | 2004-11-25 | 2011-02-23 | キヤノン株式会社 | Information acquisition method |
US20060121619A1 (en) * | 2004-12-02 | 2006-06-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Protein biomarkers and therapeutic targets in an animal model for amyotrophic lateral sclerosis |
US7572596B2 (en) * | 2004-12-02 | 2009-08-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Modulation of the neuroendoctrine system as a therapy for motor neuron disease |
US20080003599A1 (en) * | 2004-12-28 | 2008-01-03 | Dary Ekaterina L | Biological Microchip for Multiple Parallel Immunoassay of Compounds and Immunoassay Metods Using Said Microchip |
EP1838867B1 (en) * | 2005-01-06 | 2011-03-09 | Eastern Virginia Medical School | Apolipoprotein a-ii isoform as a biomarker for prostate cancer |
CN101268368A (en) | 2005-01-28 | 2008-09-17 | 儿童医疗中心有限公司 | Methods for diagnosis and prognosis of epithelial cancers |
JP2008530555A (en) * | 2005-02-09 | 2008-08-07 | コレロジック システムズ,インコーポレイテッド | Identification of bacteria and spores |
US20060183863A1 (en) * | 2005-02-14 | 2006-08-17 | Ciphergen Biosystems, Inc. | Zwitterionic polymers |
US20090247421A1 (en) * | 2005-03-23 | 2009-10-01 | Egisto Boschetti | Diverse chemical libraries bound to small particles with paramagnetic properties |
JP2008538112A (en) * | 2005-03-23 | 2008-10-09 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | Diverse chemical libraries bound to small particles with paramagnetic properties |
US8048638B2 (en) * | 2005-04-01 | 2011-11-01 | University Of Florida Research Foundation, Inc. | Biomarkers of liver injury |
US7645584B2 (en) * | 2005-04-01 | 2010-01-12 | University Of Florida Research Foundation, Inc. | Biomarkers of liver injury |
US7972867B2 (en) * | 2005-04-06 | 2011-07-05 | Quest Diagnostics Investments Incorporated | Methods for detecting vitamin D metabolites by mass spectrometry |
US7745226B2 (en) | 2005-04-06 | 2010-06-29 | Quest Diagnostics Investments Incorporated | Methods for detecting vitamin D metabolites |
BRPI0609302A2 (en) | 2005-04-15 | 2011-10-11 | Becton Dickinson Co | methods for predicting the development of sepsis and for diagnosing sepsis in an individual to be tested, microarray, kit for predicting the development of sepsis in an individual to be tested, computer program product, computer, computer system for determining if an individual is likely to develop sepsis, digital signal embedded in a carrier wave, and, graphical user interface to determine if an individual is likely to develop sepsis |
US7622273B2 (en) * | 2005-05-11 | 2009-11-24 | Gibbs Bernard F | Method for chemical and enzymatic treatment of posttranslationally modified proteins bound to a protein chip |
WO2006124628A2 (en) * | 2005-05-12 | 2006-11-23 | Correlogic Systems, Inc. | A model for classifying a biological sample in relation to breast cancer based on mass spectral data |
WO2006124644A2 (en) * | 2005-05-12 | 2006-11-23 | Board Of Regents, The University Of Texas System | Protein and antibody profiling using small molecule microarrays |
WO2006125094A2 (en) * | 2005-05-18 | 2006-11-23 | Board Of Regents, The University Of Texas System | Combinatorial selection of phosphorothioate aptamers for rnases |
US20060261267A1 (en) * | 2005-05-20 | 2006-11-23 | Agency For Science, Technology And Research | Composite MALDI matrix material and methods of using it and kits thereof in MALDI |
US7435951B2 (en) * | 2005-06-08 | 2008-10-14 | Agilent Technologies, Inc. | Ion source sample plate illumination system |
EP1896493A1 (en) | 2005-06-17 | 2008-03-12 | North Carolina A & T State University | A device including a proteinaceous factor, a recombinant proteinaceous factor, and a nucleotide sequence encoding the proteinaceous factor |
EP2993474B1 (en) | 2005-06-24 | 2019-06-12 | Vermillion, Inc. | Biomarkers for ovarian cancer: beta-2 microglobulin |
ITTO20050569A1 (en) * | 2005-08-09 | 2007-02-10 | St Microelectronics Srl | DEVICE AND METHOD OF DETERMINING THE CONTACT POSITION AND CONTACT SENSITIVE ELECTRONIC DEVICE |
US7495231B2 (en) * | 2005-09-08 | 2009-02-24 | Agilent Technologies, Inc. | MALDI sample plate imaging workstation |
DE102005044307B4 (en) * | 2005-09-16 | 2008-04-17 | Bruker Daltonik Gmbh | Ionization of desorbed molecules |
US20070202515A1 (en) * | 2005-10-12 | 2007-08-30 | Pathologica, Llc. | Promac signature application |
CA2627966A1 (en) | 2005-11-16 | 2007-05-24 | Novartis Ag | Biomarkers for anti-nogo-a antibody treatment in spinal cord injury |
WO2007061981A2 (en) * | 2005-11-21 | 2007-05-31 | Lumera Corporation | Surface plasmon resonance spectrometer with an actuator-driven angle scanning mechanism |
US20070127164A1 (en) * | 2005-11-21 | 2007-06-07 | Physical Logic Ag | Nanoscale Sensor |
US7463358B2 (en) * | 2005-12-06 | 2008-12-09 | Lumera Corporation | Highly stable surface plasmon resonance plates, microarrays, and methods |
WO2007070809A2 (en) * | 2005-12-12 | 2007-06-21 | Mcgill University | Biomarkers for babesia |
US9347945B2 (en) | 2005-12-22 | 2016-05-24 | Abbott Molecular Inc. | Methods and marker combinations for screening for predisposition to lung cancer |
ES2606015T3 (en) | 2005-12-22 | 2017-03-17 | Abbott Molecular Inc. | Methods and combinations of markers for the detection of lung cancer predisposition |
US20090215085A1 (en) * | 2006-01-27 | 2009-08-27 | Eastern Virginia Medical School | Proteomic Fingerprinting of Human IVF-Derived Embryos: Identification of Biomarkers of Developmental Potential |
JP2009527735A (en) | 2006-02-17 | 2009-07-30 | チルドレンズ メディカル センター コーポレーション | Free NGAL as a biomarker for cancer |
EP1994314A4 (en) * | 2006-03-06 | 2011-10-26 | Acs Ind Inc | Sliding sealing connector |
WO2007120999A2 (en) * | 2006-03-06 | 2007-10-25 | Bio-Rad Laboratories, Inc. | Chelating monomers and polymers |
EP2469279A1 (en) | 2006-03-11 | 2012-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Cystatin C, lysozyme and beta-2-microglobulin as biomarker for peripheral artery disease |
US20070231916A1 (en) * | 2006-03-29 | 2007-10-04 | Cangen Biotechnologies, Inc. | Apparatus and method for filtration to enhance the detection of peaks |
US20070231915A1 (en) * | 2006-03-29 | 2007-10-04 | Cangen Biotechnologies, Inc. | Apparatus and method for filtration to enhance the detection of peaks |
KR20090027608A (en) * | 2006-03-29 | 2009-03-17 | 칸젠 바이오테크날러지즈, 인코포레이티드 | Methods of predicting response to a treatment for a disease |
EP2010895A2 (en) * | 2006-03-29 | 2009-01-07 | Cangen Biotechnologies, Inc. | Apparatus and method for predicting disease |
US20070238193A1 (en) * | 2006-03-29 | 2007-10-11 | Cangen Biotechnologies, Inc. | Apparatus and method for filtration to enhance the detection of peaks |
US20070231917A1 (en) * | 2006-03-29 | 2007-10-04 | Cangen Biotechnologies, Inc. | Apparatus and method for filtration to enhance the detection of peaks |
US8518926B2 (en) * | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
WO2007123908A2 (en) * | 2006-04-18 | 2007-11-01 | Advanced Liquid Logic, Inc. | Droplet-based multiwell operations |
WO2007133714A2 (en) * | 2006-05-12 | 2007-11-22 | Stratos Biosystems, Llc | Analyte focusing biochips for affinity mass spectrometry |
CA2652251A1 (en) | 2006-05-16 | 2007-11-29 | Knopp Neurosciences, Inc. | Compositions of r(+) and s(-) pramipexole and methods for using the same |
WO2007139956A2 (en) * | 2006-05-26 | 2007-12-06 | Laboratory Corporation Of America Holdings | Methods and systems for the quantitative analysis of biomarkers |
US20080193772A1 (en) * | 2006-07-07 | 2008-08-14 | Bio-Rad Laboratories, Inc | Mass spectrometry probes having hydrophobic coatiings |
US7972794B2 (en) * | 2006-07-18 | 2011-07-05 | Quest Diagnostics Investments Incorporated | Oxidized apoA-I determination by mass spectrometry |
WO2008011158A2 (en) | 2006-07-21 | 2008-01-24 | Amgen Inc. | Method of detecting and/ or measuring hepcidin in a sample |
AT504100B9 (en) * | 2006-08-25 | 2009-12-15 | Leopold Franzens Uni Innsbruck | MATRIX-FREE MALDI MASS SPECTROMETRY |
ES2655564T3 (en) | 2006-09-07 | 2018-02-20 | Otago Innovation Limited | Biomarker for the early detection of acute heart disorders |
US8017015B2 (en) * | 2006-10-20 | 2011-09-13 | Quest Diagnostics Investments Incorporated | Monolithic column chromatography |
US20080128608A1 (en) * | 2006-11-06 | 2008-06-05 | The Scripps Research Institute | Nanostructure-initiator mass spectrometry |
JP2010511147A (en) * | 2006-11-23 | 2010-04-08 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Device for separation of analytes in samples and MALDI analysis |
US8524695B2 (en) * | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
EP2114396A4 (en) * | 2006-12-29 | 2010-03-10 | Salk Inst For Biological Studi | Methods for enhancing exercise performance |
JP4984900B2 (en) * | 2007-01-12 | 2012-07-25 | 株式会社島津製作所 | Mass spectrometry using polymer-coated microparticles |
US20080201095A1 (en) * | 2007-02-12 | 2008-08-21 | Yip Ping F | Method for Calibrating an Analytical Instrument |
EP2136843A1 (en) | 2007-03-12 | 2009-12-30 | Miraculins Inc. | Biomarkers of prostate cancer and uses thereof |
JP2010521496A (en) | 2007-03-14 | 2010-06-24 | ノップ ニューロサイエンシーズ、インク. | Synthesis of chiral purified substituted benzothiazolediamine |
AU2008236810A1 (en) | 2007-03-27 | 2008-10-16 | Board Of Regents Of The University Of Texas System | Biomarkers for ovarian cancer |
US8399486B2 (en) * | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
EP2639316A1 (en) | 2007-05-11 | 2013-09-18 | The Johns Hopkins University | Biomarkers for melanoma |
US9091695B2 (en) * | 2007-06-01 | 2015-07-28 | Laboratory Corporation Of America Holdings | Methods and systems for quantification of peptides and other analytes |
US20100184110A1 (en) * | 2007-06-06 | 2010-07-22 | Siemens Healthcare Diagnostics Inc. | Predictive diagnostics for kidney disease |
US8017403B2 (en) | 2007-06-14 | 2011-09-13 | Quest Diagnostics Investments Incorporated | Mass spectrometry method for measuring vitamin B6 in body fluid |
ES2609818T3 (en) | 2007-06-15 | 2017-04-24 | Xiamen University | Monoclonal antibodies that bind to H5 subtype avian influenza virus hemagglutinin and uses thereof |
CA3056116A1 (en) | 2007-06-22 | 2008-12-31 | Randolph Watnick | Methods and uses thereof of prosaposin |
JP2010532484A (en) | 2007-06-29 | 2010-10-07 | コレロジック システムズ,インコーポレイテッド | Predictive markers for ovarian cancer |
US11311917B2 (en) | 2007-08-09 | 2022-04-26 | Bruker Nano, Inc. | Apparatus and method for contamination identification |
US20090060786A1 (en) * | 2007-08-29 | 2009-03-05 | Gibum Kim | Microfluidic apparatus for wide area microarrays |
US20090180931A1 (en) | 2007-09-17 | 2009-07-16 | Sequenom, Inc. | Integrated robotic sample transfer device |
WO2009058331A2 (en) | 2007-10-29 | 2009-05-07 | Vermilllion, Inc. | Biomarkers for the detection of early stage ovarian cancer |
WO2009061313A1 (en) * | 2007-11-06 | 2009-05-14 | The Scripps Research Institute | Nanostructure-initiator mass spectrometry |
US20090134325A1 (en) | 2007-11-27 | 2009-05-28 | Goldman Mildred M | Methods for detecting estradiol by mass spectrometry |
US7972868B2 (en) | 2007-11-28 | 2011-07-05 | Quest Diagnostics Investments Incorporated | Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry |
WO2009070350A1 (en) | 2007-11-30 | 2009-06-04 | Siemens Healthcare Diagnostics Inc. | Adiponectin receptor fragments and methods of use |
US8030084B2 (en) | 2007-12-06 | 2011-10-04 | Quest Diagnostics Investments Incorporated | Thyroglobulin quantitation by mass spectrometry |
US8916385B2 (en) | 2007-12-13 | 2014-12-23 | Quest Diagnostics Investments, Inc. | Methods for detecting estrone by mass spectrometry |
US8004669B1 (en) | 2007-12-18 | 2011-08-23 | Plexera Llc | SPR apparatus with a high performance fluid delivery system |
TW200933195A (en) * | 2008-01-28 | 2009-08-01 | Ind Tech Res Inst | Autostereoscopic display |
EP2265641B1 (en) * | 2008-03-12 | 2018-01-24 | Otago Innovation Limited | Biomarkers |
EP2265642A4 (en) | 2008-03-12 | 2012-05-02 | Otago Innovation Ltd | Biomarkers |
US20110008903A1 (en) * | 2008-03-27 | 2011-01-13 | Valerie Paradis | Methods and kits for determining the occurrence of a liver disease in a subject |
US8669113B2 (en) | 2008-04-03 | 2014-03-11 | Becton, Dickinson And Company | Advanced detection of sepsis |
JP5258360B2 (en) * | 2008-04-14 | 2013-08-07 | 富士フイルム株式会社 | Immunochromatography measurement method and immunochromatography measurement kit |
US7776522B2 (en) | 2008-04-24 | 2010-08-17 | Becton, Dickinson And Company | Methods for diagnosing oncogenic human papillomavirus (HPV) |
US8673644B2 (en) | 2008-05-13 | 2014-03-18 | Battelle Memorial Institute | Serum markers for type II diabetes mellitus |
EP2286437A1 (en) * | 2008-06-02 | 2011-02-23 | Bio-Rad Laboratories, Inc. | Mass spectrometric detection of material transferred to a surface |
WO2010123720A1 (en) | 2009-04-23 | 2010-10-28 | Siemens Healthcare Diagnostics Inc. | Monomeric and dimeric forms of adiponectin receptor fragments and methods of use |
US7834313B2 (en) * | 2008-08-08 | 2010-11-16 | Quest Diagnostics Investments Incorporated | Mass spectrometry assay for plasma-renin |
US8106351B2 (en) | 2008-08-08 | 2012-01-31 | Quest Diagnostics Investments Incorporated | Mass spectrometry assay for plasma-renin |
JP5781436B2 (en) | 2008-08-11 | 2015-09-24 | バンヤン・バイオマーカーズ・インコーポレーテッド | Biomarker detection methods and assays for neurological conditions |
EP2334185A4 (en) | 2008-08-19 | 2011-09-21 | Knopp Neurosciences Inc | Compositions and methods of using (r)-pramipexole |
US7893399B2 (en) * | 2008-09-09 | 2011-02-22 | Quest Diagnostics Investments Incorporated | Methods for detecting dehydroepiandrosterone by mass spectrometry |
US7804063B2 (en) | 2008-10-06 | 2010-09-28 | Quest Diagnostics Investments Incorporated | Methods for detecting dihydrotestosterone by mass spectrometry |
US7952067B2 (en) | 2008-10-06 | 2011-05-31 | Quest Diagnostics Investments Incorporated | Methods for detecting vitamin C by mass spectrometry |
EP2687609B1 (en) | 2008-11-10 | 2017-01-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Method for treating solid tumor |
US8039794B2 (en) * | 2008-12-16 | 2011-10-18 | Quest Diagnostics Investments Incorporated | Mass spectrometry assay for thiopurine-S-methyl transferase activity and products generated thereby |
US7952068B2 (en) | 2008-12-16 | 2011-05-31 | Quest Diagnostics Investments Incorporated | Methods for detecting catecholamines by mass spectrometry |
US8399829B2 (en) | 2008-12-18 | 2013-03-19 | Quest Diagnostics Investments Incorporated | Vitamin B2 detection by mass spectrometry |
US20100155594A1 (en) | 2008-12-23 | 2010-06-24 | Goldman Mildred M | Mass spectrometry assay for estrogenic compounds |
WO2010075449A1 (en) * | 2008-12-24 | 2010-07-01 | Quest Diagnostics Investments Incorporated | Mass spectrometry assay for congenital adrenal hyperplasia |
US8535891B2 (en) | 2008-12-30 | 2013-09-17 | Children's Medical Center Corporation | Method of predicting acute appendicitis |
WO2010079253A2 (en) | 2009-01-09 | 2010-07-15 | Proyecto De Biomedicina Cima, S.L. | Bio-markers for diagnosing fibrosis |
WO2010087985A2 (en) | 2009-01-28 | 2010-08-05 | Yale University | Novel markers for detection of complications resulting from in utero encounters |
US8715928B2 (en) | 2009-02-13 | 2014-05-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Molecular-based method of cancer diagnosis and prognosis |
MX2011012680A (en) * | 2009-05-29 | 2012-03-06 | Univ Texas | Peptoid ligands for isolation and treatment of autoimmune t-cells. |
CN102439451B (en) * | 2009-06-02 | 2014-12-03 | 德克萨斯大学系统董事会 | Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases |
JP4993632B2 (en) * | 2009-06-16 | 2012-08-08 | 朝日インテック株式会社 | Medical guidewire |
WO2011012672A1 (en) | 2009-07-29 | 2011-02-03 | Pharnext | New diagnostic tools for alzheimer disease |
WO2011047257A1 (en) * | 2009-10-16 | 2011-04-21 | The Board Of Regents Of The University Of Texas System | Compositions and methods for producing cyclic peptoid libraries |
WO2011057021A1 (en) | 2009-11-05 | 2011-05-12 | Quest Diagnostics Investments Incorporated | Quantitation of insulin-like growth factor-i and insulin-like growth factor-ii with high-resolution mass spectrometry |
US8304248B2 (en) | 2009-11-16 | 2012-11-06 | Torres Anthony R | Protein separation via ion-exchange chromatography and associated methods, systems, and devices |
US8034627B2 (en) | 2009-12-03 | 2011-10-11 | Quest Diagnostics Investments Incorporated | Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry |
US7977117B2 (en) * | 2009-12-03 | 2011-07-12 | Quest Diagnostics Investments Incorprated | Vitamin D metabolite determination utilizing mass spectrometry following derivatization |
JP5739903B2 (en) | 2009-12-11 | 2015-06-24 | クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド | Mass spectrometry of steroidal compounds in complex samples |
JP6113504B2 (en) | 2009-12-11 | 2017-04-12 | クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド | Determination of non-derivatized non-metabolized vitamin D by mass spectrometry |
EP3366695B1 (en) | 2009-12-17 | 2021-07-07 | Children's Medical Center Corporation | Saposin-a derived peptides and uses thereof |
WO2011084751A1 (en) * | 2009-12-21 | 2011-07-14 | Quest Diagnostics Investments Incorporated | Glucagon detection and quantitation by mass spectrometry |
ES2735530T3 (en) | 2010-01-26 | 2019-12-19 | Bioregency Inc | Compositions and methods related to argininosuccinate synthetase |
WO2011149943A1 (en) | 2010-05-24 | 2011-12-01 | Ventana Midical Systems, Inc. | Method for differentiation of non-small cellung carcinoma |
US10837972B2 (en) | 2010-06-09 | 2020-11-17 | Quest Diagnostics Investments Incorporated | Mass spectrometric determination of derivatized methylmalonic acid |
AU2011282245B2 (en) | 2010-07-19 | 2017-09-28 | Otago Innovation Limited | Signal biomarkers |
US20140031250A1 (en) | 2010-10-07 | 2014-01-30 | David Tsai Ting | Biomarkers of Cancer |
WO2012051519A2 (en) | 2010-10-14 | 2012-04-19 | The Johns Hopkins University | Biomarkers of brain injury |
WO2012087438A1 (en) | 2010-11-08 | 2012-06-28 | Georgetown University | Methods for simultaneous quantification of thyroid hormones and metabolites thereof by mass spectrometry |
US10436803B2 (en) | 2010-12-28 | 2019-10-08 | Quest Diagnostics Investments Incorporated | Quantitation of insulin by tandem mass spectrometry of insulin B chain |
US9177766B2 (en) | 2010-12-30 | 2015-11-03 | Quest Diagnostics Investments Incorporated | Mass spectrometric quantitation assay for metabolites of leflunomide |
JP2014518624A (en) | 2011-05-12 | 2014-08-07 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Assay reagent for neurogranin diagnostic kit |
US8728824B2 (en) | 2011-06-22 | 2014-05-20 | Quest Diagnostics Investments Inc. | Mass spectrometric determination of fatty acids |
CA2839451A1 (en) | 2011-06-27 | 2013-01-03 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
WO2013055911A1 (en) | 2011-10-14 | 2013-04-18 | Dana-Farber Cancer Institute, Inc. | Znf365/zfp365 biomarker predictive of anti-cancer response |
AU2012340015B2 (en) | 2011-11-14 | 2017-09-21 | Alfasigma S.P.A. | Assays for selecting a treatment regimen for a subject with depression and methods for treatment |
EP2783388A4 (en) | 2011-11-23 | 2015-12-09 | Quest Diagnostics Invest Inc | Kisspeptin-54 detection by tandem mass spectrometry |
US8669519B2 (en) | 2011-12-05 | 2014-03-11 | Quest Diagnostics Investments, Inc. | Methods for detecting reverse triiodothyronine by mass spectrometry |
US9512096B2 (en) | 2011-12-22 | 2016-12-06 | Knopp Biosciences, LLP | Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
EP3560509B1 (en) | 2011-12-22 | 2024-01-31 | Children's Medical Center Corporation | Saposin-a derived peptides and uses thereof |
US8779355B2 (en) | 2011-12-28 | 2014-07-15 | Quest Diagnostics Investments, Inc. | Methods for detecting lacosamide by mass spectrometry |
RU2674153C2 (en) | 2012-01-05 | 2018-12-05 | Бостон Медикал Сентер Корпорэйшн | Slit-robo signalling for diagnosis and treatment of kidney disease |
AU2013210776B2 (en) | 2012-01-20 | 2018-11-22 | Adelaide Research & Innovation Pty Ltd | Biomarkers for gastric cancer and uses thereof |
WO2013112216A1 (en) | 2012-01-24 | 2013-08-01 | Cd Diagnostics, Llc | System for detecting infection in synovial fluid |
US9360454B2 (en) | 2012-03-02 | 2016-06-07 | Berg Llc | Methods and kits for detection of coenzyme Q10 |
IN2014DN08537A (en) | 2012-03-20 | 2015-05-15 | Otago Innovation Ltd | |
WO2013192616A1 (en) | 2012-06-22 | 2013-12-27 | Htg Molecular Diagnostics, Inc. | Molecular malignancy in melanocytic lesions |
EP2680005A1 (en) | 2012-06-28 | 2014-01-01 | Rheinische Friedrich-Wilhelms-Universität Bonn | Lipid analysis |
US9638687B2 (en) | 2012-08-28 | 2017-05-02 | Bloodworks | Biochemical markers of red blood cell storage and toxicity |
EP3392344B1 (en) | 2012-09-20 | 2021-10-27 | Quest Diagnostics Investments Incorporated | Thyroglobulin quantitation by mass spectroscopy |
AU2013202668B2 (en) | 2012-12-24 | 2014-12-18 | Adelaide Research & Innovation Pty Ltd | Inhibition of cancer growth and metastasis |
JP6301362B2 (en) | 2012-12-26 | 2018-03-28 | クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド | C-peptide detection by mass spectrometry |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
WO2014182896A1 (en) | 2013-05-10 | 2014-11-13 | Johns Hopkins University | Compositions for ovarian cancer assessment having improved specificity |
CA2913334A1 (en) | 2013-05-23 | 2014-11-27 | Iphenotype Llc | Method and system for maintaining or improving wellness |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
LT3019167T (en) | 2013-07-12 | 2021-03-25 | Knopp Biosciences Llc | Treating elevated levels of eosinophils and/or basophils |
EP3757226A3 (en) | 2013-07-17 | 2021-05-05 | The Johns Hopkins University | A multi-protein biomarker assay for brain injury detection and outcome |
WO2015020523A1 (en) | 2013-08-07 | 2015-02-12 | Stichting Vu-Vumc | Biomarkers for early diagnosis of alzheimer's disease |
HUE055850T2 (en) | 2013-08-13 | 2022-01-28 | Knopp Biosciences Llc | Compositions and methods for treating chronic urticaria |
EP3038467B1 (en) | 2013-08-13 | 2020-07-29 | Knopp Biosciences LLC | Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders |
WO2015030585A2 (en) | 2013-08-27 | 2015-03-05 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Methods for detecting post-translationally modified lysines in a polypeptide |
CN103822964B (en) * | 2013-10-21 | 2016-02-24 | 南昌大学 | Chloromycetin in neutral desorb-electron spray extraction MALDI-MS direct-detection honey |
WO2015073709A2 (en) | 2013-11-14 | 2015-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Detection of atherosclerotic cardiovascular disease risk and heart failure risk |
PL3083997T3 (en) | 2013-12-20 | 2021-04-06 | Université de Lausanne | Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine |
WO2015106003A1 (en) | 2014-01-08 | 2015-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Ras pathways as markers of protection against hiv and methods to improve vaccine efficacy |
WO2015152724A2 (en) | 2014-04-02 | 2015-10-08 | Stichting Vu-Vumc | Biomarkers for the detection of frontotemporal dementia |
WO2015164743A2 (en) | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
EP4220178A3 (en) | 2014-05-12 | 2023-08-16 | Quest Diagnostics Investments Incorporated | Quantitation of tamoxifen and metabolites thereof by mass spectrometry |
WO2015188282A1 (en) * | 2014-06-13 | 2015-12-17 | Pawliszyn Janusz B | A probe for extraction of molecules of interest from a sample |
WO2015200697A1 (en) | 2014-06-25 | 2015-12-30 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
US10222386B2 (en) | 2014-09-19 | 2019-03-05 | The Johns Hopkins University | Biomarkers of congnitive dysfunction |
US9963667B2 (en) | 2014-12-31 | 2018-05-08 | Fluidigm Canada Inc. | Structured biological samples for analysis by mass cytometry |
US20180003721A1 (en) | 2015-01-15 | 2018-01-04 | Joslin Diabetes Center | Metabolite Biomarkers Predictive Of Renal Disease In Diabetic Patients |
JP6813503B2 (en) | 2015-02-10 | 2021-01-13 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Free histone protein as a biomarker |
US11041865B2 (en) | 2015-02-20 | 2021-06-22 | The Johns Hopkins University | Biomarkers of myocardial injury |
US10324082B2 (en) | 2015-03-03 | 2019-06-18 | Quest Diagnostics Investments Llc | Methods for quantitation of insulin levels by mass spectrometry |
EP3294332A4 (en) | 2015-05-14 | 2018-12-26 | Joslin Diabetes Center, Inc. | Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration |
WO2017023929A1 (en) | 2015-08-04 | 2017-02-09 | Cd Diagnostics, Inc. | Methods for detecting adverse local tissue reaction (altr) necrosis |
US11360098B2 (en) | 2015-09-28 | 2022-06-14 | Quest Diagnostics Investments Llc | Amyloid beta detection by mass spectrometry |
WO2017099829A1 (en) | 2015-12-11 | 2017-06-15 | The General Hospital Corporation | Compositions and methods for treating drug-tolerant glioblastoma |
JP7085485B2 (en) | 2016-01-15 | 2022-06-16 | マサチューセッツ アイ アンド イヤー インファーマリー | Secretory P-glycoprotein is a non-invasive biomarker for chronic nasal sinusitis |
WO2017125406A1 (en) | 2016-01-19 | 2017-07-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting left ventricular remodeling in subjects suffering from hypertension |
CN108884495B (en) | 2016-02-08 | 2023-08-22 | 美国政府(由卫生和人类服务部的部长所代表) | Gene markers predict the response of hepatocellular carcinoma to Transcatheter Arterial Chemoembolization (TACE) |
WO2017147186A1 (en) | 2016-02-22 | 2017-08-31 | Ursure, Inc. | System and method for detecting therapeutic agents to monitor adherence to a treatment regimen |
EP3423186A4 (en) | 2016-03-02 | 2019-10-23 | JP Scientific Limited | Solid phase microextraction coating |
CA3019256A1 (en) | 2016-05-10 | 2017-11-16 | Jp Scientific Limited | System and method for desorbing and detecting an analyte sorbed on a solid phase microextraction device |
KR101747038B1 (en) | 2016-06-27 | 2017-06-15 | 이현영 | Nanopolymer Having Heteromorphic Polymer Structure, Preparation Method Thereof, Nucleic Acid Reaction Composition Containing Thereof, and Method of Detecting or Quantifying Nucleic Acid Using Nucleic Acid Reaction Composition Containing Thereof |
CN110366558A (en) | 2016-10-28 | 2019-10-22 | 班扬生物标记公司 | For the antibody and correlation technique of ubiquitin c-terminal hydrolase-l 1 (UCH-L1) and glial fibrillary acid protein (GFAP) |
US11448648B2 (en) | 2016-11-11 | 2022-09-20 | Ascendant Diagnostics, LLC | Compositions and methods for diagnosing and differentiating systemic juvenile idiopathic arthritis and Kawasaki disease |
JP7337701B2 (en) | 2017-03-31 | 2023-09-04 | クエスト ダイアグノスティックス インヴェストメンツ エルエルシー | Method for quantification of insulin and C-peptide |
DE102017206155A1 (en) | 2017-04-11 | 2018-10-11 | Robert Bosch Gmbh | Desorption of nucleic acids |
MX2020001325A (en) | 2017-07-31 | 2020-07-13 | Quest Diagnostics Invest Llc | Apolipoprotein e isotype detection by mass spectrometry. |
US11860141B2 (en) | 2017-08-14 | 2024-01-02 | Quest Diagnostics Investments Llc | Detection and quantitation of guanidinoacetate, creatine, and creatinine by mass spectrometry |
KR102702206B1 (en) | 2017-09-25 | 2024-09-02 | 프레드 허친슨 캔서 센터 | High-efficiency targeted in situ genome-wide profiling |
CN112533613A (en) | 2018-02-06 | 2021-03-19 | 通用医疗公司 | Repeated RNA as biomarker for tumor immune response |
GB201802123D0 (en) | 2018-02-09 | 2018-03-28 | Metabolomic Diagnostics Ltd | A method of processomg a biological sample |
JP6916446B2 (en) * | 2018-09-13 | 2021-08-11 | 日本電信電話株式会社 | Base station management method, base station management device and program |
WO2020053380A1 (en) | 2018-09-14 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of amniotic fluid peptides for predicting postnatal renal function in congenital anomalies of the kidney and the urinary tract |
US20220018852A1 (en) | 2018-11-20 | 2022-01-20 | Inserm (Institute National De Ka Santé Et De La Recherche Médicale) | Methods and kits for detecting liver dysfunction in a subject |
EP3677693A1 (en) | 2019-01-03 | 2020-07-08 | Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO | Transpochimeric gene trancripts (tcgts) as cancer biomarkers |
IL291806A (en) | 2019-10-10 | 2022-06-01 | Regeneron Pharma | Liquid chromatography-mass spectrometry (lc-ms) methods for analyzing ampholyte lot variation |
CN115552034A (en) | 2020-01-31 | 2022-12-30 | 瑞泽恩制药公司 | Use of liquid chromatography and mass spectrometry for the characterization of oligonucleotides |
EP4133285A1 (en) | 2020-04-09 | 2023-02-15 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and compositions to determine the quality of red blood cell units |
IL296664A (en) | 2020-04-24 | 2022-11-01 | Hoffmann La Roche | Enzyme and pathway modulation with sulfhydryl compounds and their derivatives |
CN115916405A (en) * | 2020-05-20 | 2023-04-04 | 普度研究基金会 | Integrated synthesis and analysis system and method of use |
US12116637B2 (en) | 2020-07-24 | 2024-10-15 | The Regents Of The University Of Michigan | Compositions and methods for detecting and treating high grade subtypes of uterine cancer |
EP4229222A2 (en) | 2020-10-19 | 2023-08-23 | Dana-Farber Cancer Institute, Inc. | Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy |
AU2021368138A1 (en) | 2020-11-02 | 2023-06-22 | Trethera Corporation | Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof |
CN112540118B (en) * | 2020-12-03 | 2022-03-11 | 福州大学 | Method for rapidly detecting metal ions based on mercaptobenzoic acid-assisted laser desorption ionization mass spectrum |
CA3213700A1 (en) | 2021-03-17 | 2022-09-22 | Nissui Corporation | Method of purification and purified products |
EP4347889A1 (en) | 2021-05-28 | 2024-04-10 | Centre Hospitalier Universitaire Vaudois (CHUV) | Novel incrna controlling cardiac fibrosis |
WO2023122723A1 (en) | 2021-12-23 | 2023-06-29 | The Broad Institute, Inc. | Panels and methods for diagnosing and treating lung cancer |
US12105102B2 (en) | 2022-03-30 | 2024-10-01 | University Of Utah Research Foundation | Methods for quantifying insulin-like growth factor-1 and insulin-like growth factor-2 |
WO2024074685A1 (en) | 2022-10-07 | 2024-04-11 | Institut National de la Santé et de la Recherche Médicale | Use of albumin isoforms profiles for the characterization of the etiology and severity of liver injuries |
WO2024196732A1 (en) | 2023-03-17 | 2024-09-26 | Quest Diagnostics Investments Llc | Improved quantitation of testosterone in multiplexed samples by mass spectrometry |
Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896661A (en) * | 1974-01-09 | 1975-07-29 | Stanford Research Inst | Method of coupling thin layer chromatograph with mass spectrometer |
US4022876A (en) * | 1973-06-21 | 1977-05-10 | Stanford Research Institute | Mass spectrometric immunoassay |
US4295046A (en) * | 1975-09-11 | 1981-10-13 | Leybold Heraeus Gmbh | Mass spectrometer |
US4296332A (en) * | 1979-12-28 | 1981-10-20 | Sperry Corporation | Sprocket hole sensing detector for moving translucent paper sheets |
US4298332A (en) * | 1978-04-08 | 1981-11-03 | Katashi Aoki | Nozzle device for molding plastics |
US4454233A (en) * | 1981-10-21 | 1984-06-12 | Wang Associates | Method of tagged immunoassay |
US4468468A (en) * | 1981-06-27 | 1984-08-28 | Bayer Aktiengesellschaft | Process for the selective analysis of individual trace-like components in gases and liquid |
US4686366A (en) * | 1985-05-15 | 1987-08-11 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Laser mass spectrometer |
US4694167A (en) * | 1985-11-27 | 1987-09-15 | Atom Sciences, Inc. | Double pulsed time-of-flight mass spectrometer |
US4705616A (en) * | 1986-09-15 | 1987-11-10 | Sepragen Corporation | Electrophoresis-mass spectrometry probe |
US4902627A (en) * | 1985-02-05 | 1990-02-20 | The United States Of America As Represented By The Secretary Of The Navy | Method for detecting amine-containing drugs in body fluids by sims |
US4988879A (en) * | 1987-02-24 | 1991-01-29 | The Board Of Trustees Of The Leland Stanford Junior College | Apparatus and method for laser desorption of molecules for quantitation |
US5003059A (en) * | 1988-06-20 | 1991-03-26 | Genomyx, Inc. | Determining DNA sequences by mass spectrometry |
US5045694A (en) * | 1989-09-27 | 1991-09-03 | The Rockefeller University | Instrument and method for the laser desorption of ions in mass spectrometry |
US5078135A (en) * | 1989-05-31 | 1992-01-07 | Board Of Regents, The University Of Texas System | Apparatus for in vivo analysis of biological compounds in blood or tissue by microdialysis and mass spectrometry |
US5118937A (en) * | 1989-08-22 | 1992-06-02 | Finnigan Mat Gmbh | Process and device for the laser desorption of an analyte molecular ions, especially of biomolecules |
US5124267A (en) * | 1984-05-10 | 1992-06-23 | Schering Aktiengesellschaft | Method for the determination of small substance quantities of medicines, of endogenous or other chemical compounds in biological material |
US5171989A (en) * | 1992-01-24 | 1992-12-15 | Board Of Trustees Of Leland Stanford Jr. University | Method and apparatus for continuous sample ice matrix production for laser desorption in mass spectrometry |
US5209919A (en) * | 1990-07-13 | 1993-05-11 | Regents Of The University Of California | Method of measurement in biological systems |
US5547835A (en) * | 1993-01-07 | 1996-08-20 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
US5719060A (en) * | 1993-05-28 | 1998-02-17 | Baylor College Of Medicine | Method and apparatus for desorption and ionization of analytes |
US6020208A (en) * | 1994-05-27 | 2000-02-01 | Baylor College Of Medicine | Systems for surface-enhanced affinity capture for desorption and detection of analytes |
US6225047B1 (en) * | 1997-06-20 | 2001-05-01 | Ciphergen Biosystems, Inc. | Use of retentate chromatography to generate difference maps |
US6228047B1 (en) * | 1997-07-28 | 2001-05-08 | 1274515 Ontario Inc. | Method and apparatus for performing peritoneal dialysis |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3201264A1 (en) * | 1982-01-16 | 1983-07-28 | Leybold-Heraeus GmbH, 5000 Köln | LASER MICRO PROBE |
DE3221681A1 (en) * | 1982-06-08 | 1983-12-08 | Bayer Ag, 5090 Leverkusen | Mass spectrometer with an external sample holder |
DE3321681A1 (en) | 1983-06-15 | 1984-12-20 | Fogra Deutsche Forschungsgesellschaft für Druck- und Reproduktionstechnik e.V., 8000 München | Process for the removal of volatile substances from layers |
US4665192A (en) * | 1984-03-19 | 1987-05-12 | The Rockefeller University | 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole |
US6060237A (en) * | 1985-02-26 | 2000-05-09 | Biostar, Inc. | Devices and methods for optical detection of nucleic acid hybridization |
FR2586657B1 (en) * | 1985-09-04 | 1991-03-22 | Lapouyade Sa | DEVICE FOR GRIPPING SUPPORTS OR LOAD CONTAINERS |
JPS63124543A (en) * | 1986-11-14 | 1988-05-28 | Hitachi Electronics Eng Co Ltd | Plate chucking mechanism |
JPH01197211A (en) * | 1988-01-30 | 1989-08-08 | Canon Inc | Device for driving pallet |
DE3809504C1 (en) * | 1988-03-22 | 1989-09-21 | Bruker - Franzen Analytik Gmbh, 2800 Bremen, De | |
JPH0249209U (en) * | 1988-09-29 | 1990-04-05 | ||
GB2235529B (en) * | 1989-08-23 | 1993-07-28 | Finnigan Mat Ltd | Method of preparing samples for laser spectrometry analysis |
GB2236185B (en) * | 1989-08-22 | 1994-03-23 | Finnigan Mat Gmbh | Process,specimen and device for making an analyte available for an investigation |
GB2235528B (en) * | 1989-08-23 | 1993-07-28 | Finnigan Mat Ltd | Method of preparing samples for laser spectrometry analysis |
GB2236184B (en) * | 1989-09-12 | 1993-07-28 | Finnigan Mat Ltd | Method of preparing samples for laser spectrometry analysis |
US5029919A (en) * | 1990-02-15 | 1991-07-09 | Bauer John K | Pneumatic shock absorber for an automobile bumper having venting means |
US5073713A (en) * | 1990-05-29 | 1991-12-17 | Battelle Memorial Institute | Detection method for dissociation of multiple-charged ions |
ES2067852T3 (en) * | 1990-06-08 | 1995-04-01 | Mannesmann Ag | SHELVES INSTALLATION. |
WO1992013629A1 (en) * | 1991-01-31 | 1992-08-20 | Wayne State University | A method for analyzing an organic sample |
US5317932A (en) * | 1992-02-28 | 1994-06-07 | The Dow Chemical Company | Sample probe |
US5605798A (en) * | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
DE69430909T2 (en) * | 1993-03-19 | 2003-02-27 | Sequenom, Inc. | DNA SEQUENCE DETERMINATION BY MASS SPECTROMETRY ON THE WAY OF DEGRADATION WITH EXONUCLEASE |
US20020037517A1 (en) * | 1993-05-28 | 2002-03-28 | Hutchens T. William | Methods for sequencing biopolymers |
WO1996037777A1 (en) * | 1995-05-23 | 1996-11-28 | Nelson Randall W | Mass spectrometric immunoassay |
CA2221250C (en) * | 1995-06-07 | 2007-11-20 | Arizona Board Of Regents | A sample presentation apparatus for mass spectrometry |
EP1046036A4 (en) | 1997-07-29 | 2003-08-27 | James S Huston | Methods for obtaining probes of peptide function |
CN1204592C (en) * | 1999-04-27 | 2005-06-01 | 赛弗根生物系统股份有限公司 | Probes for gas phase ion spectrometer |
-
1994
- 1994-05-27 CA CA002512290A patent/CA2512290C/en not_active Expired - Lifetime
- 1994-05-27 EP EP03012514A patent/EP1347493A3/en not_active Withdrawn
- 1994-05-27 NZ NZ267842A patent/NZ267842A/en not_active IP Right Cessation
- 1994-05-27 WO PCT/US1994/006064 patent/WO1994028418A1/en active IP Right Grant
- 1994-05-27 DE DE69432791T patent/DE69432791T2/en not_active Expired - Lifetime
- 1994-05-27 EP EP94919287A patent/EP0700521B1/en not_active Expired - Lifetime
- 1994-05-27 ES ES94919287T patent/ES2201077T3/en not_active Expired - Lifetime
- 1994-05-27 JP JP50101195A patent/JP3639594B2/en not_active Expired - Lifetime
- 1994-05-27 AU AU70483/94A patent/AU676582B2/en not_active Expired
- 1994-05-27 AT AT94919287T patent/ATE242485T1/en active
- 1994-05-27 DK DK94919287T patent/DK0700521T3/en active
- 1994-05-27 CA CA002163426A patent/CA2163426C/en not_active Expired - Lifetime
- 1994-05-27 PT PT94919287T patent/PT700521E/en unknown
-
1995
- 1995-06-07 US US08/483,357 patent/US5719060A/en not_active Expired - Lifetime
-
1997
- 1997-01-17 US US08/785,636 patent/US6027942A/en not_active Expired - Lifetime
- 1997-01-17 US US08/785,637 patent/US5894063A/en not_active Expired - Fee Related
-
1998
- 1998-06-10 US US09/095,407 patent/US6124137A/en not_active Expired - Lifetime
- 1998-07-27 US US09/123,253 patent/US7071003B2/en not_active Expired - Fee Related
-
1999
- 1999-08-24 JP JP23764699A patent/JP3457228B2/en not_active Expired - Lifetime
-
2000
- 2000-12-20 US US09/742,494 patent/US6528320B2/en not_active Expired - Lifetime
-
2001
- 2001-03-15 US US09/809,657 patent/US6734022B2/en not_active Expired - Fee Related
-
2003
- 2003-08-12 JP JP2003292545A patent/JP3818990B2/en not_active Expired - Fee Related
- 2003-12-05 US US10/728,442 patent/US20040191922A1/en not_active Abandoned
-
2006
- 2006-02-03 US US11/347,495 patent/US7449150B2/en not_active Expired - Fee Related
Patent Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4022876A (en) * | 1973-06-21 | 1977-05-10 | Stanford Research Institute | Mass spectrometric immunoassay |
US3896661A (en) * | 1974-01-09 | 1975-07-29 | Stanford Research Inst | Method of coupling thin layer chromatograph with mass spectrometer |
US4295046A (en) * | 1975-09-11 | 1981-10-13 | Leybold Heraeus Gmbh | Mass spectrometer |
US4298332A (en) * | 1978-04-08 | 1981-11-03 | Katashi Aoki | Nozzle device for molding plastics |
US4296332A (en) * | 1979-12-28 | 1981-10-20 | Sperry Corporation | Sprocket hole sensing detector for moving translucent paper sheets |
US4468468A (en) * | 1981-06-27 | 1984-08-28 | Bayer Aktiengesellschaft | Process for the selective analysis of individual trace-like components in gases and liquid |
US4454233A (en) * | 1981-10-21 | 1984-06-12 | Wang Associates | Method of tagged immunoassay |
US5124267A (en) * | 1984-05-10 | 1992-06-23 | Schering Aktiengesellschaft | Method for the determination of small substance quantities of medicines, of endogenous or other chemical compounds in biological material |
US4902627A (en) * | 1985-02-05 | 1990-02-20 | The United States Of America As Represented By The Secretary Of The Navy | Method for detecting amine-containing drugs in body fluids by sims |
US4686366A (en) * | 1985-05-15 | 1987-08-11 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Laser mass spectrometer |
US4694167A (en) * | 1985-11-27 | 1987-09-15 | Atom Sciences, Inc. | Double pulsed time-of-flight mass spectrometer |
US4705616A (en) * | 1986-09-15 | 1987-11-10 | Sepragen Corporation | Electrophoresis-mass spectrometry probe |
US4988879A (en) * | 1987-02-24 | 1991-01-29 | The Board Of Trustees Of The Leland Stanford Junior College | Apparatus and method for laser desorption of molecules for quantitation |
US5003059A (en) * | 1988-06-20 | 1991-03-26 | Genomyx, Inc. | Determining DNA sequences by mass spectrometry |
US5078135A (en) * | 1989-05-31 | 1992-01-07 | Board Of Regents, The University Of Texas System | Apparatus for in vivo analysis of biological compounds in blood or tissue by microdialysis and mass spectrometry |
US5118937A (en) * | 1989-08-22 | 1992-06-02 | Finnigan Mat Gmbh | Process and device for the laser desorption of an analyte molecular ions, especially of biomolecules |
US5045694A (en) * | 1989-09-27 | 1991-09-03 | The Rockefeller University | Instrument and method for the laser desorption of ions in mass spectrometry |
US5209919A (en) * | 1990-07-13 | 1993-05-11 | Regents Of The University Of California | Method of measurement in biological systems |
US5171989A (en) * | 1992-01-24 | 1992-12-15 | Board Of Trustees Of Leland Stanford Jr. University | Method and apparatus for continuous sample ice matrix production for laser desorption in mass spectrometry |
US5547835A (en) * | 1993-01-07 | 1996-08-20 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
US5894063A (en) * | 1993-05-28 | 1999-04-13 | Baylor College Of Medicine | Surface-enhanced neat desorption for disorption and detection of analytes |
US5719060A (en) * | 1993-05-28 | 1998-02-17 | Baylor College Of Medicine | Method and apparatus for desorption and ionization of analytes |
US6027942A (en) * | 1993-05-28 | 2000-02-22 | Baylor College Medicine | Surface-enhanced affinity capture for desorption and detection or analytes |
US6124137A (en) * | 1993-05-28 | 2000-09-26 | Baylor College Of Medicine | Surface-enhanced photolabile attachment and release for desorption and detection of analytes |
US6528320B2 (en) * | 1993-05-28 | 2003-03-04 | Baylor College Of Medicine | Method and apparatus for desorption and ionization of analytes |
US6734022B2 (en) * | 1993-05-28 | 2004-05-11 | Baylor College Of Medicine | Method and apparatus for desorption and ionization of analytes |
US6020208A (en) * | 1994-05-27 | 2000-02-01 | Baylor College Of Medicine | Systems for surface-enhanced affinity capture for desorption and detection of analytes |
US6225047B1 (en) * | 1997-06-20 | 2001-05-01 | Ciphergen Biosystems, Inc. | Use of retentate chromatography to generate difference maps |
US6579719B1 (en) * | 1997-06-20 | 2003-06-17 | Ciphergen Biosystems, Inc. | Retentate chromatography and protein chip arrays with applications in biology and medicine |
US6811969B1 (en) * | 1997-06-20 | 2004-11-02 | Ciphergen Biosystems, Inc. | Retentate chromatography—profiling with biospecific interaction adsorbents |
US6844165B2 (en) * | 1997-06-20 | 2005-01-18 | Ciphergen Biosystems, Inc. | Retentate chromatography and protein chip arrays with applications in biology and medicine |
US6881586B2 (en) * | 1997-06-20 | 2005-04-19 | Ciphergen Biosystems, Inc. | Retentate chromatography and protein chip arrays with applications in biology and medicine |
US6228047B1 (en) * | 1997-07-28 | 2001-05-08 | 1274515 Ontario Inc. | Method and apparatus for performing peritoneal dialysis |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5894063A (en) | Surface-enhanced neat desorption for disorption and detection of analytes | |
US6020208A (en) | Systems for surface-enhanced affinity capture for desorption and detection of analytes | |
US7413909B2 (en) | Method and apparatus for desorption and ionization of analytes | |
JP3930563B2 (en) | Surface plasmon resonance mass spectrometry | |
EP3306310B1 (en) | Method for quantifying monoclonal antibody | |
JP2001281222A (en) | Analytical method for object to be analyzed by mass spectrometry | |
EP4241083A1 (en) | Derivatization of at least one analyte of interest for mass spec measurements in patient samples |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |